Bijlagen bij conceptrichtlijnmodules cluster Cognitieve stoornissen en Dementie

4e cyclus modulair onderhoud

Inhoudsopgave

Bijlagen bij module 1 – Deprescribing cholinesteraseremmers bij dementie

Implementatietabel

De implementatietabel brengt in kaart welke factoren de uitvoering van een aanbeveling bevorderen of belemmeren, en welke aanvullende acties nodig zijn voor succesvolle invoering. De adviseur en (cluster)werkgroep vullen de tabel in op basis van gerichte vragen over het onderliggende probleem, relevante randvoorwaarden en mogelijke knelpunten. Op basis hiervan wordt geconcludeerd of een extra implementatie-impuls wenselijk is.

Vraag	***Antwoord:*** *Kruis aan en licht toe/ beschrijf*		***Toelichting keuze:***
I1. Wat was het onderliggende probleem om deze uitgangsvraag uit te werken?	**x**	**Ongewenste praktijkvariatie**	Zie introductie
		Nieuwe evidentie	
		Anders	
I2. Maak een inschatting over hoeveel patiënten het ongeveer gaat waar de aanbeveling betrekking op heeft?		**< 1000**	
		< 5000	
	x	**5000-40.000**	
		> 40.000	
I3. Is de aanbeveling onderdeel van een bredere set interventies of verwant aan andere richtlijnen of modules? Zo ja, hoe verhoudt zij zich daartoe en moet hiermee rekening worden gehouden bij de implementatie, of kan de aanbeveling als losstaand worden beschouwd?		**Ja**	
	x	**Nee**	
I4. Belemmeringen en kansen op verschillende niveaus voor landelijke toepassing van de aanbeveling:		**Belemmerende factoren**	**Bevorderende factoren/ kansen**
Richtlijn/ klinisch traject (innovatie)	**x**	Geen	Verspreiding
Zorgverleners (artsen en verpleegkundigen)	**x**	Geen	Kennis nemen van de richtlijn
Patiënt/ cliënt (naasten)			
Sociale context			
Organisatorische context			
Financiële en juridische context			
I5. A) Welke personen/partijen zijn van belang bij het toepassen van de aanbeveling in de praktijk? (kruis aan) **B) Wat is er nodig van deze personen/partijen om de aanbeveling in de praktijk te kunnen brengen?** *Denk aan aanpassingen in gedrag, werkwijzen, beleid, samenwerking of andere randvoorwaarden.*		**A**	**B**
		Patiënt/ cliënt (naaste)	
	x	Professional	Kennis nemen van de richtlijn
	x	Beroepsvereniging, nl	Onder de aandacht brengen
		Ziekenhuis (raad van bestuur/UMCNL (voorheen NFU)/NVZ)	

		Zorgverzekeraars/ NZa	
		Zorginstituut [duiding nodig]	
		Anders	
I6. Binnen welk tijdsbestek moet de aanbeveling zijn geïmplementeerd?	**x**	< 1 jaar	
		binnen 2-3 jaar	
I7. Conclusie: is er extra actie en/of ondersteuning nodig voor implementatie van de aanbeveling? *De reguliere implementatieroutes (publicatie en disseminatie via officiele kanalen, opname in professionele standaarden, scholing en nascholing, gebruik van bestaande ICT systemen, audits en visitaties) van de richtlijnmodule alleen is onvoldoende.*		Ja	
	x	Nee	
I8. Plaatsing op de Landelijke Implementatieagenda Medisch Specialistische zorg is gewenst. *Het gaat om zorg die (grotendeels) wordt uitgevoerd binnen de ziekenhuismuren. Succesvolle implementatie vraagt om actieve betrokkenheid en samenwerking van meerdere relevante partijen binnen de zorgpraktijk.*		Ja *	
	x	Nee	

**Deze aanbeveling komt mogelijk in aanmerking voor plaatsing op de Landelijke Implementatieagenda van het programma Zorg Evaluatie & Gepast Gebruik (ZE&GG), waarin alle betrokken partijen in de medisch-specialistische zorg samenwerken aan de implementatie van bewezen beste zorg. De Federatie levert namens het veld goed onderbouwde aanbevelingen aan, die zijn getoetst op de behoefte aan een implementatie-impuls. De onderwerpen op de Implementatieagenda zijn onderdeel van landelijke zorginkoopafspraken tussen zorgverzekeraars en zorgaanbieders. Voor de beoordeling van aanbevelingen uit richtlijnen wordt gebruikgemaakt van de implementatietabel. Op basis hiervan kunnen we de andere partijen goed informeren en gezamenlijk besluiten of plaatsing op de Implementatieagenda passend is.*

Risk of Bias tables

Risk of bias studies included in Parsons (2021)

For further details about the risk of bias assessment of the studies included in Parsons (2021), see https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009081.pub2/full



5

Risk of bias individual study (Moo, 2021)

Study reference (first author, publication year)	**Was the allocation sequence adequately generated?** Definitely yes Probably yes Probably no Definitely no	**Was the allocation adequately concealed?** Definitely yes Probably yes Probably no Definitely no	**Blinding: Was knowledge of the allocated interventions adequately prevented? Were patients, healthcare providers, data collectors, outcome assessors, data analysts blinded?** Definitely yes Probably yes Probably no Definitely no	**Was loss to follow-up (missing outcome data) infrequent?** Definitely yes Probably yes Probably no Definitely no	**Are reports of the study free of selective outcome reporting?** Definitely yes Probably yes Probably no Definitely no	**Was the study apparently free of other problems that could put it at a risk of bias?** Definitely yes Probably yes Probably no Definitely no	**Overall risk of bias** **If applicable/necessary, per outcome measure** **LOW** **Some concerns** **HIGH**
Moo, 2021	Definitely yes Reason: The randomization sequence was generated by the study pharmacist using a random-number generator, which is an appropriate and unbiased method.	Definitely yes Reason: Only the pharmacist was aware of the allocation; all other investigators, participants, and caregivers remained blinded until study completion.	Definitely yes Reason: The trial was double-blind. Participants, healthcare providers, data collectors, and outcome assessors were blinded to group allocation.	Probably yes Reason: Some attrition occurred (approximately 15%), but it was balanced between groups and unlikely to have biased the results.	Probably yes Reason: Primary and secondary outcomes (medication discontinuation decision, symptom scales) were reported as planned, with no evidence of selective outcome reporting.	Definitely no Reason: The study was underpowered, and had to be terminated, had a small sample size (n=6), low recruitment rate (4.5%), and limited generalizability (mainly male veterans), increasing potential for selection bias.	**Some concerns**

Table of excluded studies

Reference	Reason for exclusion
O'Regan J, Lanctôt KL, Mazereeuw G, Herrmann N. Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2015 Nov;76(11):e1424-31. doi: 10.4088/JCP.14r09237. PMID: 26646039.	This review is less recent and complete compared to Parsons (2021). All studies included in O'Regan are included in Parsons (2021) as well.

Literature search strategy

Algemene informatie

Cluster/richtlijn: Cluster cognitieve stoornissen en dementie (cyclus 4)	
Uitgangsvraag/modules: UV1 Op welk moment is het stoppen van cholinesteraseremmers aan te bevelen bij patiënten met dementie die cholinesteraseremmers gebruiken?	
Database(s): Embase.com, Ovid/Medline all	Datum: 29 juli 2025 en 8 augustus 2025
Periode: SRs vanaf 2005 en RCTs vanaf 17-10-2020 (searchdate SR Parsons 2021)	Talen: geen restrictie
Literatuurspecialist: Alies Oost	Rayyan: https://new.rayyan.ai/reviews/1558307/screening
BMI-zoekblokken: voor verschillende opdrachten wordt (deels) gebruik gemaakt van de zoekblokken van BMI-Online https://blocks.bmi-online.nl/	
Toelichting: De sleutelartikelen worden gevonden met de search. In eerste instantie zijn de SRs gescreend. Op 8 augustus 2025 is aanvullend gezocht naar RCTs vanaf 17-10-2020 (searchdate SR Parsons 2021).	
Te gebruiken voor richtlijntekst: A systematic literature search was performed by a medical information specialist using the following bibliographic databases: Embase.com and Ovid/Medline all. Both databases were searched from 2005 to July 29th 2025 for systematic reviews and from October 10th 2020 to August 8th 2025 for RCTs. Systematic searches were completed using a combination of controlled vocabulary and natural language keywords. The overall search strategy was derived from the following primary search concepts: (1) dementia; (2) cholinesterase inhibitors; (3) discontinuation. Duplicates were removed using EndNote software. After deduplication a total of 333 records were imported for title/abstract screening.	

Zoekopbrengst 29-07-2025

	EMBASE	**OVID/MEDLINE**	**Ontdubbeld**
SR	237	83	239
RCT	690	218	748
Observationele studies	411	167	406
Totaal			**239***

****gescreend in Rayyan***

Zoekopbrengst 08-08-2025

	EMBASE	**OVID/MEDLINE**	**Ontdubbeld**
RCT	88	20	94
Totaal			**94***

****gescreend in Rayyan***

Zoekstrategie 29-07-2025

Embase.com

No.	Query	Results
#1	'dementia'/exp OR 'parkinson disease'/exp OR dement*:ti,ab,kw OR alzheimer*:ti,ab,kw OR huntington*:ti,ab,kw OR ((lewy NEAR/1 bod*):ti,ab,kw) OR ((creutzfeld* NEAR/1 (jakob* OR jacob*)):ti,ab,kw) OR amenti*:ti,ab,kw OR (((pick OR picks OR 'pick s') NEAR/1 disease*):ti,ab,kw) OR parkinson*:ti,ab,kw	819081

#2	'cholinesterase inhibitor'/exp OR (((cholinesterase* OR acetylcholinesterase* OR 'choline esterase*') NEAR/2 (inhibit* OR block* OR anti)):ti,ab,kw) OR anticholinesterase*:ti,ab,kw OR 'donepezil'/exp OR 'aricept':ti,ab,kw OR 'donepezil':ti,ab,kw OR eranz:ti,ab,kw OR 'galantamine'/exp OR 'galantamin*':ti,ab,kw OR 'galanthamin*':ti,ab,kw OR lycoremin*:ti,ab,kw OR nivalin*:ti,ab,kw OR 'razadyn*':ti,ab,kw OR reminyl:ti,ab,kw OR 'rivastigmine'/exp OR 'exelon':ti,ab,kw OR 'rivastigmin*':ti,ab,kw	120341
#3	'deprescription'/exp OR 'drug withdrawal'/exp OR 'drug dose reduction'/exp OR withdraw*:ti OR reduce*:ti OR reducing*:ti OR reduct*:ti OR stop*:ti OR continue:ti OR continued:ti OR continuing:ti OR discontinu*:ti OR deprescrib*:ti OR deprescrip*:ti OR (((withdraw* OR cessat* OR abstinence OR reduce* OR reducing* OR reduct* OR decreas* OR taper* OR stop* OR 'carr* on' OR continu* OR discontinu* OR maintain* OR maintenance OR 'come off' OR remain* OR deprescrib* OR 'de prescrib*' OR deprescription* OR 'de prescription*' OR 'length of therapy' OR 'duration of therapy') NEAR/6 (cholinesterase* OR cheis OR acetylcholinesterase* OR 'choline esterase*' OR anticholinesterase* OR aricept OR donepezil OR eranz OR galantamin* OR galanthamin* OR lycoremin* OR nivalin* OR razadyn* OR reminyl OR exelon OR rivastigmin* OR 'cognitive enhancer*')):ti,ab,kw)	1033042
#4	#1 AND #2 AND #3 NOT ('conference abstract'/it OR 'clinical trial':dtype) NOT (('editorial'/it OR 'letter'/it OR 'note'/it) NOT 'evidence based medicine'/exp) NOT (('animal'/exp OR 'animal experiment'/exp OR 'animal model'/exp OR 'nonhuman'/exp) NOT 'human'/exp)	2226
#5	#4 AND [2005-2025]/py	1931
#6	'meta analysis'/exp OR 'systematic review'/exp OR 'scoping review'/exp OR 'rapid review'/exp OR 'umbrella review'/exp OR 'cochrane database of systematic reviews'/jt OR 'network meta-analysis'/exp OR 'networkmeta analy*':ti,ab,kw OR 'networkmetaanaly*':ti,ab,kw OR metaanaly*:ti,ab,kw OR 'meta analy*':ti,ab,kw OR metanaly*:ti,ab,kw OR prisma:ti,ab,kw OR prospero:ti,ab,kw OR metaanali*:ti,ab,kw OR 'meta anali*':ti,ab,kw OR metanali*:ti,ab,kw OR (((systemati* OR scoping OR umbrella OR 'structured literature') NEAR/3 (review* OR overview*)):ti,ab,kw) OR (((structured OR systemic*) NEAR/3 (review* OR overview* OR synth*) NEAR/3 literature):ti,ab,kw) OR ((systemic* NEAR/1 review*):ti,ab,kw) OR (((systemati* OR literature OR database* OR 'data base*') NEAR/10 search*):ti,ab,kw) OR (((structured OR comprehensive* OR systemic*) NEAR/3 search*):ti,ab,kw) OR (((literature NEAR/3 (review* OR overview*)):ti,ab,kw) AND (search*:ti,ab,kw OR database*:ti,ab,kw OR 'data base*':ti,ab,kw)) OR (('data extraction*':ti,ab,kw OR 'data source*':ti,ab,kw) AND ('study selection*':ti,ab,kw OR 'studies selection*':ti,ab,kw)) OR ('search strateg*':ti,ab,kw AND 'selection criteria*':ti,ab,kw) OR ('data source*':ti,ab,kw AND 'data synth*':ti,ab,kw) OR medline*:ti,ab,kw OR pubmed*:ti,ab,kw OR 'pub med*':ti,ab,kw OR embase:ti,ab,kw OR cochrane*:ti,ab,kw OR (((critical* OR rapid*) NEAR/2 (review* OR overview* OR synth*)):ti) OR ((((critical* OR rapid*) NEAR/3 (review* OR overview* OR synth*)):ab) AND (search*:ab OR database*:ab OR 'data base*':ab)) OR metasynth*:ti,ab,kw OR 'meta synth*':ti,ab,kw OR 'review* of review*':ti,ab,kw	1143402
#7	'clinical trial'/exp OR 'randomization'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp OR 'placebo'/exp OR 'prospective study'/exp OR rct:ab,ti OR random*:ab,ti OR 'single blind':ab,ti OR 'randomized controlled trial'/exp OR placebo*:ab,ti	4863511
#8	'major clinical study'/de OR 'clinical study'/de OR 'family study'/de OR 'longitudinal study'/de OR 'retrospective study'/de OR 'prospective study'/de OR 'cohort analysis'/de OR 'case control study'/de OR 'comparative study'/exp OR 'control group'/de OR 'controlled study'/de OR 'controlled clinical trial'/de OR 'crossover procedure'/de OR 'double blind procedure'/de OR 'phase 2 clinical trial'/de OR 'phase 3 clinical trial'/de OR 'phase 4 clinical trial'/de OR 'pretest posttest design'/de OR 'pretest posttest control group design'/de OR 'quasi experimental study'/de OR 'single blind procedure'/de OR 'triple blind procedure'/de OR ((cohort NEAR/1 (study OR studies)):ab,ti) OR (('case control' NEAR/1 (study OR studies)):ab,ti) OR (('follow up' NEAR/1 (study OR studies)):ab,ti) OR (observational NEAR/1 (study OR studies)) OR ((epidemiologic NEAR/1 (study OR studies)):ab,ti) OR (('cross sectional' NEAR/1 (study OR studies)):ab,ti) OR (((control OR controlled) NEAR/6 trial):ti,ab,kw) OR (((control OR controlled) NEAR/6 (study OR studies)):ti,ab,kw) OR (((control OR controlled) NEAR/1 active):ti,ab,kw) OR 'open label*':ti,ab,kw OR (((double OR two OR three OR multi OR trial) NEAR/1 (arm OR arms)):ti,ab,kw) OR ((allocat* NEAR/10	18837767

	(arm OR arms)):ti,ab,kw) OR placebo*:ti,ab,kw OR 'sham-control*':ti,ab,kw OR (((single OR double OR triple OR assessor) NEAR/1 (blind* OR masked)):ti,ab,kw) OR nonrandom*:ti,ab,kw OR 'non-random*':ti,ab,kw OR 'quasi-experiment*':ti,ab,kw OR crossover:ti,ab,kw OR 'cross over':ti,ab,kw OR 'parallel group*':ti,ab,kw OR 'factorial trial':ti,ab,kw OR ((phase NEAR/5 (study OR trial)):ti,ab,kw) OR ((case* NEAR/6 (matched OR control*)):ti,ab,kw) OR ((match* NEAR/6 (pair OR pairs OR cohort* OR control* OR group* OR healthy OR age OR sex OR gender OR patient* OR subject* OR participant*)):ti,ab,kw) OR ((propensity NEAR/6 (scor* OR match*)):ti,ab,kw) OR versus:ti OR vs:ti OR compar*:ti OR ((compar* NEAR/1 study):ti,ab,kw) OR (('observational study'/de OR 'cross-sectional study'/de OR 'multicenter study'/de OR 'correlational study'/de OR 'follow up'/de OR cohort*:ti,ab,kw OR 'follow up':ti,ab,kw OR followup:ti,ab,kw OR longitudinal*:ti,ab,kw OR prospective*:ti,ab,kw OR retrospective*:ti,ab,kw OR observational*:ti,ab,kw OR 'cross sectional*':ti,ab,kw OR cross?ectional*:ti,ab,kw OR multicent*:ti,ab,kw OR 'multi-cent*':ti,ab,kw OR consecutive*:ti,ab,kw) AND (group:ti,ab,kw OR groups:ti,ab,kw OR subgroup*:ti,ab,kw OR versus:ti,ab,kw OR vs:ti,ab,kw OR compar*:ti,ab,kw OR 'odds ratio*':ab OR 'relative odds':ab OR 'risk ratio*':ab OR 'relative risk*':ab OR 'rate ratio':ab OR aor:ab OR arr:ab OR rrr:ab OR (((or' OR 'rr') NEAR/6 ci):ab)))	
#9	#5 AND #6	237
#10	#5 AND #7 NOT #9	690
#11	#5 AND #8 NOT (#9 OR #10)	411
#12	#9 OR #10 OR #11	1338

Ovid/Medline

#	Searches	Results
1	exp Dementia/ or exp Parkinsonian Disorders/ or dement*.ti,ab,kf. or alzheimer*.ti,ab,kf. or huntington*.ti,ab,kf. or (lewy adj1 bod*).ti,ab,kf. or (creutzfeld* adj1 (jakob* or jacob*)).ti,ab,kf. or amenti*.ti,ab,kf. or ((pick or picks or 'pick s') adj1 disease*).ti,ab,kf. or parkinson*.ti,ab,kf.	516566
2	exp Cholinesterase Inhibitors/ or ((cholinesterase* or acetylcholinesterase* or 'choline esterase*') adj2 (inhibit* or block* or anti)).ti,ab,kf. or anticholinesterase*.ti,ab,kf. or exp Donepezil/ or 'aricept'.ti,ab,kf. or 'donepezil'.ti,ab,kf. or eranz.ti,ab,kf. or exp Galantamine/ or 'galantamin*'.ti,ab,kf. or 'galanthamin*'.ti,ab,kf. or lycoremin*.ti,ab,kf. or nivalin*.ti,ab,kf. or 'razadyn*'.ti,ab,kf. or reminyl.ti,ab,kf. or exp Rivastigmine/ or 'exelon'.ti,ab,kf. or 'rivastigmin*'.ti,ab,kf.	66662
3	exp Deprescriptions/ or exp Drug Tapering/ or exp Inappropriate Prescribing/ or withdraw*.ti. or reduce*.ti. or reducing*.ti. or reduct*.ti. or stop*.ti. or continue.ti. or continued.ti. or continuing.ti. or discontinu*.ti. or deprescrib*.ti. or deprescrip*.ti. or ((withdraw* or cessat* or abstinence or reduce* or reducing* or reduct* or decreas* or taper* or stop* or 'carr* on' or continu* or discontinu* or maintain* or maintenance or 'come off' or remain* or deprescrib* or 'de prescrib*' or deprescription* or 'de prescription*' or 'length of therapy' or 'duration of therapy') adj6 (cholinesterase* or ChEIs or acetylcholinesterase* or 'choline esterase*' or anticholinesterase* or aricept or donepezil or eranz or galantamin* or galanthamin* or lycoremin* or nivalin* or razadyn* or reminyl or exelon or rivastigmin* or 'cognitive enhancer*')).ti,ab,kf.	533350
4	(1 and 2 and 3) not ((exp animals/ or exp models, animal/) not humans/) not ((letter/ or comment/ or editorial/) not (exp Clinical Trial/ or exp Meta-Analysis/ or exp Scoping Review/ or exp Systematic Review/))	987
5	limit 4 to yr="2005 -Current"	810
6	exp Meta-Analysis/ or exp Network Meta-Analysis/ or exp Systematic Review/ or (networkmeta analy* or networkmetaanaly* or metaanaly* or meta analy* or metanaly* or prisma or prospero or metaanali* or meta anali* or metanali*).ti,ab,kf. or ((systemati* or scoping or umbrella or structured literature) adj3 (review* or overview*)).ti,ab,kf. or ((structured or systemic*) adj3 (review* or overview* or synth*) adj3 literature).ti,ab,kf. or (systemic* adj1 review*).ti,ab,kf. or ((systemati* or literature or database* or data base*) adj10 search*).ti,ab,kf. or ((structured or comprehensive* or systemic*) adj3 search*).ti,ab,kf. or ((literature adj3 (review* or overview*)) and (search* or database* or data base*)).ti,ab,kf. or ((data extraction* or data source*) and (study selection* or studies	848202

	selection*)).ti,ab,kf. or (search strateg* and selection criteria*).ti,ab,kf. or (data source* and data synth*).ti,ab,kf. or (medline* or pubmed* or pub med* or embase or cochrane*).ti,ab,kf. or cochrane.jw. or ((critical* or rapid*) adj2 (review* or overview* or synth*)).ti. or (((critical* or rapid*) adj3 (review* or overview* or synth*)) and (search* or database* or data base*)).ab. or metasynth*.ti,ab,kf. or meta synth*.ti,ab,kf.	
7	exp clinical trial/ or randomized controlled trial/ or exp clinical trials as topic/ or randomized controlled trials as topic/ or Random Allocation/ or Double-Blind Method/ or Single-Blind Method/ or (clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or controlled clinical trial or randomized controlled trial or multicenter study or clinical trial).pt. or random*.ti,ab. or (clinic* adj trial*).tw. or ((singl* or doubl* or treb* or tripl*) adj (blind$3 or mask$3)).tw. or Placebos/ or placebo*.tw.	2922396
8	Case-control Studies/ or clinical trial, phase ii/ or clinical trial, phase iii/ or clinical trial, phase iv/ or comparative study/ or control groups/ or controlled before-after studies/ or controlled clinical trial/ or double-blind method/ or historically controlled study/ or matched-pair analysis/ or single-blind method/ or (((control or controlled) adj6 (study or studies or trial)) or (compar* adj (study or studies)) or ((control or controlled) adj1 active) or "open label*" or ((double or two or three or multi or trial) adj (arm or arms)) or (allocat* adj10 (arm or arms)) or placebo* or "sham-control*" or ((single or double or triple or assessor) adj1 (blind* or masked)) or nonrandom* or "non-random*" or "quasi-experiment*" or "parallel group*" or "factorial trial" or "pretest posttest" or (phase adj5 (study or trial)) or (case* adj6 (matched or control*)) or (match* adj6 (pair or pairs or cohort* or control* or group* or healthy or age or sex or gender or patient* or subject* or participant*)) or (propensity adj6 (scor* or match*))).ti,ab,kf. or (confounding adj6 adjust*).ti,ab. or (versus or vs or compar*).ti. or exp cohort studies/ or epidemiologic studies/ or ((multicenter study/ or observational study/ or seroepidemiologic studies/ or (cohort* or 'follow up' or followup or longitudinal* or prospective* or retrospective* or observational* or multicent* or 'multi-cent*' or consecutive*).ti,ab,kf.) and ((group or groups or subgroup* or versus or vs or compar*).ti,ab,kf. or ('odds ratio*' or 'relative odds' or 'risk ratio*' or 'relative risk*' or aor or arr or rrr).ab. or (("OR" or "RR") adj6 CI).ab.)) or Case control.tw. or cohort.tw. or Cohort analy$.tw. or (Follow up adj (study or studies)).tw. or (observational adj (study or studies)).tw. or Longitudinal.tw. or Retrospective*.tw. or prospective*.tw. or consecutive*.tw. or Cross sectional.tw. or Cross-sectional studies/ or historically controlled study/ or interrupted time series analysis/	8116336
9	5 and 6	83
10	(5 and 7) not 9	218
11	(5 and 8) not (9 or 10)	167
12	9 or 10 or 11	468

Zoekstrategie 08-08-2025

Embase.com

No.	Query	Results
#1	'dementia'/exp OR 'parkinson disease'/exp OR dement*:ti,ab,kw OR alzheimer*:ti,ab,kw OR huntington*:ti,ab,kw OR ((lewy NEAR/1 bod*):ti,ab,kw) OR ((creutzfeld* NEAR/1 (jakob* OR jacob*)):ti,ab,kw) OR amenti*:ti,ab,kw OR (((pick OR picks OR 'pick s') NEAR/1 disease*):ti,ab,kw) OR parkinson*:ti,ab,kw	820506
#2	'cholinesterase inhibitor'/exp OR (((cholinesterase* OR acetylcholinesterase* OR 'choline esterase*') NEAR/2 (inhibit* OR block* OR anti)):ti,ab,kw) OR anticholinesterase*:ti,ab,kw OR 'donepezil'/exp OR 'aricept':ti,ab,kw OR 'donepezil':ti,ab,kw OR eranz:ti,ab,kw OR 'galantamine'/exp OR 'galantamin*':ti,ab,kw OR 'galanthamin*':ti,ab,kw OR lycoremin*:ti,ab,kw OR nivalin*:ti,ab,kw OR 'razadyn*':ti,ab,kw OR reminyl:ti,ab,kw OR 'rivastigmine'/exp OR 'exelon':ti,ab,kw OR 'rivastigmin*':ti,ab,kw	120460
#3	'deprescription'/exp OR 'drug withdrawal'/exp OR 'drug dose reduction'/exp OR withdraw*:ti OR reduce*:ti OR reducing*:ti OR reduct*:ti OR stop*:ti OR continue:ti OR continued:ti OR continuing:ti OR discontinu*:ti OR deprescrib*:ti OR deprescrip*:ti OR (((withdraw* OR cessat* OR abstinence OR reduce* OR reducing* OR reduct* OR decreas* OR taper* OR stop* OR 'carr* on' OR continu* OR discontinu* OR maintain* OR maintenance OR 'come off' OR remain* OR	1035150

	deprescrib* OR 'de prescrib*' OR deprescription* OR 'de prescription*' OR 'length of therapy' OR 'duration of therapy') NEAR/6 (cholinesterase* OR cheis OR acetylcholinesterase* OR 'choline esterase*' OR anticholinesterase* OR aricept OR donepezil OR eranz OR galantamin* OR galanthamin* OR lycoremin* OR nivalin* OR razadyn* OR reminyl OR exelon OR rivastigmin* OR 'cognitive enhancer*')):ti,ab,kw)	
#4	#1 AND #2 AND #3 NOT ('conference abstract'/it OR 'clinical trial':dtype) NOT (('editorial'/it OR 'letter'/it OR 'note'/it) NOT 'evidence based medicine'/exp) NOT (('animal'/exp OR 'animal experiment'/exp OR 'animal model'/exp OR 'nonhuman'/exp) NOT 'human'/exp)	2229
#5	#4 AND [17-10-2020]/sd	454
#6	'meta analysis'/exp OR 'systematic review'/exp OR 'scoping review'/exp OR 'rapid review'/exp OR 'umbrella review'/exp OR 'cochrane database of systematic reviews'/jt OR 'network meta-analysis'/exp OR 'networkmeta analy*':ti,ab,kw OR 'networkmetaanaly*':ti,ab,kw OR metaanaly*:ti,ab,kw OR 'meta analy*':ti,ab,kw OR metanaly*:ti,ab,kw OR prisma:ti,ab,kw OR prospero:ti,ab,kw OR metaanali*:ti,ab,kw OR 'meta anali*':ti,ab,kw OR metanali*:ti,ab,kw OR (((systemati* OR scoping OR umbrella OR 'structured literature') NEAR/3 (review* OR overview*)):ti,ab,kw) OR (((structured OR systemic*) NEAR/3 (review* OR overview* OR synth*) NEAR/3 literature):ti,ab,kw) OR ((systemic* NEAR/1 review*):ti,ab,kw) OR (((systemati* OR literature OR database* OR 'data base*') NEAR/10 search*):ti,ab,kw) OR (((structured OR comprehensive* OR systemic*) NEAR/3 search*):ti,ab,kw) OR (((literature NEAR/3 (review* OR overview*)):ti,ab,kw) AND (search*:ti,ab,kw OR database*:ti,ab,kw OR 'data base*':ti,ab,kw)) OR (('data extraction*':ti,ab,kw OR 'data source*':ti,ab,kw) AND ('study selection*':ti,ab,kw OR 'studies selection*':ti,ab,kw)) OR ('search strateg*':ti,ab,kw AND 'selection criteria*':ti,ab,kw) OR ('data source*':ti,ab,kw AND 'data synth*':ti,ab,kw) OR medline*:ti,ab,kw OR pubmed*:ti,ab,kw OR 'pub med*':ti,ab,kw OR embase:ti,ab,kw OR cochrane*:ti,ab,kw OR (((critical* OR rapid*) NEAR/2 (review* OR overview* OR synth*)):ti) OR ((((critical* OR rapid*) NEAR/3 (review* OR overview* OR synth*)):ab) AND (search*:ab OR database*:ab OR 'data base*':ab)) OR metasynth*:ti,ab,kw OR 'meta synth*':ti,ab,kw OR 'review* of review*':ti,ab,kw	1147765
#7	'clinical trial'/exp OR 'randomization'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp OR 'placebo'/exp OR 'prospective study'/exp OR rct:ab,ti OR random*:ab,ti OR 'single blind':ab,ti OR 'randomized controlled trial'/exp OR placebo*:ab,ti	4875123
#8	#5 AND #6	62
#9	#5 AND #7 NOT #8	88

Ovid/Medline

#	Searches	Results
1	exp Dementia/ or exp Parkinsonian Disorders/ or dement*.ti,ab,kf. or alzheimer*.ti,ab,kf. or huntington*.ti,ab,kf. or (lewy adj1 bod*).ti,ab,kf. or (creutzfeld* adj1 (jakob* or jacob*)).ti,ab,kf. or amenti*.ti,ab,kf. or ((pick or picks or 'pick s') adj1 disease*).ti,ab,kf. or parkinson*.ti,ab,kf.	517323
2	exp Cholinesterase Inhibitors/ or ((cholinesterase* or acetylcholinesterase* or 'choline esterase*') adj2 (inhibit* or block* or anti)).ti,ab,kf. or anticholinesterase*.ti,ab,kf. or exp Donepezil/ or 'aricept'.ti,ab,kf. or 'donepezil'.ti,ab,kf. or eranz.ti,ab,kf. or exp Galantamine/ or 'galantamin*'.ti,ab,kf. or 'galanthamin*'.ti,ab,kf. or lycoremin*.ti,ab,kf. or nivalin*.ti,ab,kf. or 'razadyn*'.ti,ab,kf. or reminyl.ti,ab,kf. or exp Rivastigmine/ or 'exelon'.ti,ab,kf. or 'rivastigmin*'.ti,ab,kf.	66719
3	exp Deprescriptions/ or exp Drug Tapering/ or exp Inappropriate Prescribing/ or withdraw*.ti. or reduce*.ti. or reducing*.ti. or reduct*.ti. or stop*.ti. or continue.ti. or continued.ti. or continuing.ti. or discontinu*.ti. or deprescrib*.ti. or deprescrip*.ti. or ((withdraw* or cessat* or abstinence or reduce* or reducing* or reduct* or decreas* or taper* or stop* or 'carr* on' or continu* or discontinu* or maintain* or maintenance or 'come off' or remain* or deprescrib* or 'de prescrib*' or deprescription* or 'de prescription*' or 'length of therapy' or 'duration of therapy') adj6 (cholinesterase* or ChEIs or acetylcholinesterase* or 'choline esterase*' or anticholinesterase* or aricept or donepezil or eranz or galantamin* or galanthamin* or lycoremin* or nivalin* or razadyn* or reminyl or exelon or rivastigmin* or 'cognitive enhancer*')).ti,ab,kf.	534058

4	(1 and 2 and 3) not ((exp animals/ or exp models, animal/) not humans/) not ((letter/ or comment/ or editorial/) not (exp Clinical Trial/ or exp Meta-Analysis/ or exp Scoping Review/ or exp Systematic Review/))	988
5	limit 4 to dt="20201017-20250808"	201
6	exp Meta-Analysis/ or exp Network Meta-Analysis/ or exp Systematic Review/ or (networkmeta analy* or networkmetaanaly* or metaanaly* or meta analy* or metanaly* or prisma or prospero or metaanali* or meta anali* or metanali*).ti,ab,kf. or ((systemati* or scoping or umbrella or structured literature) adj3 (review* or overview*)).ti,ab,kf. or ((structured or systemic*) adj3 (review* or overview* or synth*) adj3 literature).ti,ab,kf. or (systemic* adj1 review*).ti,ab,kf. or ((systemati* or literature or database* or data base*) adj10 search*).ti,ab,kf. or ((structured or comprehensive* or systemic*) adj3 search*).ti,ab,kf. or ((literature adj3 (review* or overview*)) and (search* or database* or data base*)).ti,ab,kf. or ((data extraction* or data source*) and (study selection* or studies selection*)).ti,ab,kf. or (search strateg* and selection criteria*).ti,ab,kf. or (data source* and data synth*).ti,ab,kf. or (medline* or pubmed* or pub med* or embase or cochrane*).ti,ab,kf. or cochrane.jw. or ((critical* or rapid*) adj2 (review* or overview* or synth*)).ti. or (((critical* or rapid*) adj3 (review* or overview* or synth*)) and (search* or database* or data base*)).ab. or metasynth*.ti,ab,kf. or meta synth*.ti,ab,kf.	850747
7	exp clinical trial/ or randomized controlled trial/ or exp clinical trials as topic/ or randomized controlled trials as topic/ or Random Allocation/ or Double-Blind Method/ or Single-Blind Method/ or (clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or controlled clinical trial or randomized controlled trial or multicenter study or clinical trial).pt. or random*.ti,ab. or (clinic* adj trial*).tw. or ((singl* or doubl* or treb* or tripl*) adj (blind$3 or mask$3)).tw. or Placebos/ or placebo*.tw.	2927470
8	5 and 6	24
9	(5 and 7) not 8	20

Bijlagen bij module 2 – Diagnose dementie bij bipolaire stoornis

Implementatietabel

Vraag	***Antwoord:*** *Kruis aan en licht toe/ beschrijf*		***Toelichting keuze:***
I1. Wat was het onderliggende probleem om deze uitgangsvraag uit te werken?	**x**	**Ongewenste praktijkvariatie**	Ontbreken richtlijn leidde tot andere inzet van diagnostiek in deze populatie.
		Nieuwe evidentie	
		Anders	
I2. Maak een inschatting over hoeveel patiënten het ongeveer gaat waar de aanbeveling betrekking op heeft?		**< 1000**	
	x	**< 5000**	
		5000-40.000	
		> 40.000	
I3. Is de aanbeveling onderdeel van een bredere set interventies of verwant aan andere richtlijnen of modules? Zo ja, hoe verhoudt zij zich daartoe en moet hiermee rekening worden gehouden bij de implementatie, of kan de aanbeveling als losstaand worden beschouwd?		**Ja**	
	x	**Nee**	
I4. Belemmeringen en kansen op verschillende niveaus voor landelijke toepassing van de aanbeveling:		**Belemmerende factoren**	**Bevorderende factoren/ kansen**
Richtlijn/ klinisch traject (innovatie)	**x**	Geen, standaardzorg maar geeft meer helderheid voor deze specifieke populatie.	Onder de aandacht brengen
Zorgverleners (artsen en verpleegkundigen)			
Patiënt/ cliënt (naasten)			
Sociale context			
Organisatorische context			
Financiële en juridische context			
I5. A) Welke personen/partijen zijn van belang bij het toepassen van de aanbeveling in de praktijk? (kruis aan) **B) Wat is er nodig van deze personen/partijen om de aanbeveling in de praktijk te kunnen brengen?** *Denk aan aanpassingen in gedrag, werkwijzen, beleid, samenwerking of andere randvoorwaarden.*		**A**	**B**
		Patiënt/ cliënt (naaste)	
	x	Professional	Kennis nemen van de richtlijn
	x	Beroepsvereniging, nl NVvP, NVKG, NVN, NIP	Onder de aandacht brengen.
		Ziekenhuis (raad van bestuur/UMCNL (voorheen NFU)/NVZ)	
		Zorgverzekeraars/ NZa	
		Zorginstituut [duiding nodig]	

		Anders	
I6. Binnen welk tijdsbestek moet de aanbeveling zijn geïmplementeerd?	**x**	< 1 jaar	
		binnen 2-3 jaar	
I7. Conclusie: is er extra actie en/of ondersteuning nodig voor implementatie van de aanbeveling? *De reguliere implementatieroutes (publicatie en disseminatie via officiele kanalen, opname in professionele standaarden, scholing en nascholing, gebruik van bestaande ICT systemen, audits en visitaties) van de richtlijnmodule alleen is onvoldoende.*		Ja	
	x	Nee	
I8. Plaatsing op de Landelijke Implementatieagenda Medisch Specialistische zorg is gewenst. *Het gaat om zorg die (grotendeels) wordt uitgevoerd binnen de ziekenhuismuren. Succesvolle implementatie vraagt om actieve betrokkenheid en samenwerking van meerdere relevante partijen binnen de zorgpraktijk.*		Ja *	
	x	Nee	

**Deze aanbeveling komt mogelijk in aanmerking voor plaatsing op de Landelijke Implementatieagenda van het programma Zorg Evaluatie & Gepast Gebruik (ZE&GG), waarin alle betrokken partijen in de medisch-specialistische zorg samenwerken aan de implementatie van bewezen beste zorg. De Federatie levert namens het veld goed onderbouwde aanbevelingen aan, die zijn getoetst op de behoefte aan een implementatie-impuls. De onderwerpen op de Implementatieagenda zijn onderdeel van landelijke zorginkoopafspraken tussen zorgverzekeraars en zorgaanbieders. Voor de beoordeling van aanbevelingen uit richtlijnen wordt gebruikgemaakt van de implementatietabel. Op basis hiervan kunnen we de andere partijen goed informeren en gezamenlijk besluiten of plaatsing op de Implementatieagenda passend is.*

Risk of Bias tables

Not applicable.

Table of excluded studies

Reference	Reason for exclusion
Aprahamian I, Radanovic M, Nunes PV, Ladeira RB, Forlenza OV. The use of the Clock Drawing Test in bipolar disorder with or without dementia of Alzheimer's type. Arq Neuropsiquiatr. 2014 Dec;72(12):913-8. doi: 10.1590/0004-282X20140153. Epub 2014 Dec 2. PMID: 25465779.	Wrong population
Aprahamian I, Radanovic M, Nunes PV, Ladeira RB, Forlenza OV. The use of the Clock Drawing Test in bipolar disorder with or without dementia of Alzheimer's type. Arq Neuropsiquiatr. 2014 Dec;72(12):913-8. doi: 10.1590/0004-282X20140153. Epub 2014 Dec 2. PMID: 25465779.	Wrong population

Literature search strategy

Algemene informatie

Cluster/richtlijn: Cluster Cognitieve stoornissen en dementie/ Dementie	
Uitgangsvraag/modules: Wat is de aanbevolen strategie (en wat zijn verstorende factoren) om dementie te diagnosticeren bij patiënten met een bipolaire stoornis en het vermoeden op dementie?	
Database(s): Embase.com, Ovid/Medline all	Datum: 29 september 2025
Periode: vanaf 2005	Talen: geen restrictie
Literatuurspecialist: Alies Oost	Rayyan: https://new.rayyan.ai/reviews/1646096/screening

BMI-zoekblokken: voor verschillende opdrachten wordt (deels) gebruik gemaakt van de zoekblokken van BMI-Online https://blocks.bmi-online.nl/
Toelichting: Er zijn geen sleutelartikelen voor deze search.
Te gebruiken voor richtlijntekst: A systematic literature search was performed by a medical information specialist using the following bibliographic databases: Embase.com and Ovid/Medline all. Both databases were searched from 2005 to September 29th 2025 for systematic reviews, RCTs and observational studies. Systematic searches were completed using a combination of controlled vocabulary and natural language keywords. The overall search strategy was derived from the following primary search concepts: (1) dementia; (2) bipolar disorder; (3) diagnostic accuracy. Duplicates were removed using EndNote software. After deduplication a total of 662 records were imported for title/abstract screening.

Zoekopbrengst

	EMBASE	**OVID/MEDLINE**	**Ontdubbeld**
SR	136	48	143
RCT	131	31	138
Observationele studies	369	96	381
Totaal	636	175	**662***

****in Rayyan***

5 ***Zoekstrategie***

Embase.com

No.	Query	Results
#1	'dementia'/exp OR dement*:ti,ab,kw OR alzheimer*:ti,ab,kw OR huntington*:ti,ab,kw OR ((lewy NEAR/1 bod*):ti,ab,kw) OR ((creutzfeld* NEAR/1 (jakob* OR jacob*)):ti,ab,kw) OR amenti*:ti,ab,kw OR (((pick OR picks OR 'pick s') NEAR/1 disease*):ti,ab,kw)	623092
#2	'mania'/exp OR ((bipolar NEAR/3 (disorder* OR illness* OR disease* OR depress* OR psycho*)):ti,ab,kw) OR (((manic OR mania) NEAR/3 (depress* OR bipolar OR disorder* OR psycho*)):ti,ab,kw) OR cyclophrenia:ti,ab,kw OR cyclothymia:ti,ab,kw OR ((cyclothymic NEAR/3 (depress* OR disorder* OR peronality)):ti,ab,kw)	129589
#3	'sensitivity and specificity'/de OR sensitivity:ab,ti OR specificity:ab,ti OR predict*:ab,ti OR 'roc curve':ab,ti OR 'receiver operator':ab,ti OR 'receiver operators':ab,ti OR likelihood:ab,ti OR 'diagnostic error'/exp OR 'diagnostic accuracy'/exp OR 'diagnostic test accuracy study'/exp OR 'inter observer':ab,ti OR 'intra observer':ab,ti OR interobserver:ab,ti OR intraobserver:ab,ti OR validity:ab,ti OR kappa:ab,ti OR reliability:ab,ti OR reproducibility:ab,ti OR ((test NEAR/2 're-test'):ab,ti) OR ((test NEAR/2 'retest'):ab,ti) OR 'reproducibility'/exp OR accuracy:ab,ti OR 'differential diagnosis'/exp OR 'validation study'/de OR 'measurement precision'/exp OR 'diagnostic value'/exp OR 'reliability'/exp OR 'predictive value'/exp OR ppv:ti,ab,kw OR npv:ti,ab,kw OR (((false OR true) NEAR/3 (negative OR positive)):ti,ab)	7136909
#4	#1 AND #2 AND #3 NOT ('conference abstract'/it OR 'clinical trial':dtype) NOT (('editorial'/it OR 'letter'/it OR 'note'/it) NOT 'evidence based medicine'/exp) NOT (('animal'/exp OR 'animal experiment'/exp OR 'animal model'/exp OR 'nonhuman'/exp) NOT 'human'/exp)	1094
#5	#4 AND [2005-2026]/py	964
#6	'meta analysis'/exp OR 'systematic review'/exp OR 'scoping review'/exp OR 'rapid review'/exp OR 'umbrella review'/exp OR 'cochrane database of systematic reviews'/jt OR 'network meta-analysis'/exp OR 'networkmeta analy*':ti,ab,kw OR 'networkmetaanaly*':ti,ab,kw OR metaanaly*:ti,ab,kw OR 'meta analy*':ti,ab,kw OR metanaly*:ti,ab,kw OR prisma:ti,ab,kw OR prospero:ti,ab,kw OR metaanali*:ti,ab,kw OR 'meta anali*':ti,ab,kw OR metanali*:ti,ab,kw OR (((systemati* OR scoping OR umbrella OR 'structured literature') NEAR/3 (review* OR overview*)):ti,ab,kw) OR (((structured OR systemic*) NEAR/3 (review* OR overview* OR synth*) NEAR/3 literature):ti,ab,kw) OR ((systemic* NEAR/1 review*):ti,ab,kw) OR (((systemati* OR	1165469

	literature OR database* OR 'data base*') NEAR/10 search*):ti,ab,kw) OR (((structured OR comprehensive* OR systemic*) NEAR/3 search*):ti,ab,kw) OR (((literature NEAR/3 (review* OR overview*)):ti,ab,kw) AND (search*:ti,ab,kw OR database*:ti,ab,kw OR 'data base*':ti,ab,kw)) OR (('data extraction*':ti,ab,kw OR 'data source*':ti,ab,kw) AND ('study selection*':ti,ab,kw OR 'studies selection*':ti,ab,kw)) OR ('search strateg*':ti,ab,kw AND 'selection criteria*':ti,ab,kw) OR ('data source*':ti,ab,kw AND 'data synth*':ti,ab,kw) OR medline*:ti,ab,kw OR pubmed*:ti,ab,kw OR 'pub med*':ti,ab,kw OR embase:ti,ab,kw OR cochrane*:ti,ab,kw OR (((critical* OR rapid*) NEAR/2 (review* OR overview* OR synth*)):ti) OR ((((critical* OR rapid*) NEAR/3 (review* OR overview* OR synth*)):ab) AND (search*:ab OR database*:ab OR 'data base*':ab)) OR metasynth*:ti,ab,kw OR 'meta synth*':ti,ab,kw OR 'review* of review*':ti,ab,kw	
#7	'clinical trial'/exp OR 'randomization'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp OR 'placebo'/exp OR 'prospective study'/exp OR rct:ab,ti OR random*:ab,ti OR 'single blind':ab,ti OR 'randomized controlled trial'/exp OR placebo*:ab,ti	4913009
#8	'major clinical study'/de OR 'clinical study'/de OR 'family study'/de OR 'longitudinal study'/de OR 'retrospective study'/de OR 'prospective study'/de OR 'cohort analysis'/de OR 'case control study'/de OR 'comparative study'/exp OR 'control group'/de OR 'controlled study'/de OR 'controlled clinical trial'/de OR 'crossover procedure'/de OR 'double blind procedure'/de OR 'phase 2 clinical trial'/de OR 'phase 3 clinical trial'/de OR 'phase 4 clinical trial'/de OR 'pretest posttest design'/de OR 'pretest posttest control group design'/de OR 'quasi experimental study'/de OR 'single blind procedure'/de OR 'triple blind procedure'/de OR ((cohort NEAR/1 (study OR studies)):ab,ti) OR (('case control' NEAR/1 (study OR studies)):ab,ti) OR (('follow up' NEAR/1 (study OR studies)):ab,ti) OR (observational NEAR/1 (study OR studies)) OR ((epidemiologic NEAR/1 (study OR studies)):ab,ti) OR (('cross sectional' NEAR/1 (study OR studies)):ab,ti) OR (((control OR controlled) NEAR/6 trial):ti,ab,kw) OR (((control OR controlled) NEAR/6 (study OR studies)):ti,ab,kw) OR (((control OR controlled) NEAR/1 active):ti,ab,kw) OR 'open label*':ti,ab,kw OR (((double OR two OR three OR multi OR trial) NEAR/1 (arm OR arms)):ti,ab,kw) OR ((allocat* NEAR/10 (arm OR arms)):ti,ab,kw) OR placebo*:ti,ab,kw OR 'sham-control*':ti,ab,kw OR (((single OR double OR triple OR assessor) NEAR/1 (blind* OR masked)):ti,ab,kw) OR nonrandom*:ti,ab,kw OR 'non-random*':ti,ab,kw OR 'quasi-experiment*':ti,ab,kw OR crossover:ti,ab,kw OR 'cross over':ti,ab,kw OR 'parallel group*':ti,ab,kw OR 'factorial trial':ti,ab,kw OR ((phase NEAR/5 (study OR trial)):ti,ab,kw) OR ((case* NEAR/6 (matched OR control*)):ti,ab,kw) OR ((match* NEAR/6 (pair OR pairs OR cohort* OR control* OR group* OR healthy OR age OR sex OR gender OR patient* OR subject* OR participant*)):ti,ab,kw) OR ((propensity NEAR/6 (scor* OR match*)):ti,ab,kw) OR versus:ti OR vs:ti OR compar*:ti OR ((compar* NEAR/1 study):ti,ab,kw) OR (('observational study'/de OR 'cross-sectional study'/de OR 'multicenter study'/de OR 'correlational study'/de OR 'follow up'/de OR cohort*:ti,ab,kw OR 'follow up':ti,ab,kw OR followup:ti,ab,kw OR longitudinal*:ti,ab,kw OR prospective*:ti,ab,kw OR retrospective*:ti,ab,kw OR observational*:ti,ab,kw OR 'cross sectional*':ti,ab,kw OR cross?ectional*:ti,ab,kw OR multicent*:ti,ab,kw OR 'multi-cent*':ti,ab,kw OR consecutive*:ti,ab,kw) AND (group:ti,ab,kw OR groups:ti,ab,kw OR subgroup*:ti,ab,kw OR versus:ti,ab,kw OR vs:ti,ab,kw OR compar*:ti,ab,kw OR 'odds ratio*':ab OR 'relative odds':ab OR 'risk ratio*':ab OR 'relative risk*':ab OR 'rate ratio':ab OR aor:ab OR arr:ab OR rrr:ab OR ((('or' OR 'rr') NEAR/6 ci):ab)))	19057857
#9	#5 AND #6	136
#10	#5 AND #7 NOT #9	131
#11	#5 AND #8 NOT (#9 OR #10)	369
#12	#9 OR #10 OR #11	636

Ovid/Medline

#	Searches	Results
1	exp Dementia/ or dement*.ti,ab,kf. or alzheimer*.ti,ab,kf. or huntington*.ti,ab,kf. or (lewy adj1 bod*).ti,ab,kf. or (creutzfeld* adj1 (jakob* or jacob*)).ti,ab,kf. or amenti*.ti,ab,kf. or ((pick or picks or 'pick s') adj1 disease*).ti,ab,kf.	386709
2	exp "Bipolar and Related Disorders"/ or exp Mania/ or (bipolar adj3 (disorder* or illness* or disease* or depress* or psycho*)).ti,ab,kf. or ((manic or mania) adj3	69266

	(depress* or bipolar or disorder* or psycho*)).ti,ab,kf. or cyclophrenia.ti,ab,kf. or cyclothymia.ti,ab,kf. or (cyclothymic adj3 (depress* or disorder* or peronality)).ti,ab,kf.	
3	exp "Sensitivity and Specificity"/ or (sensitivity or specificity).ti,ab. or (predict* or ROC-curve or receiver-operator*).ti,ab. or (likelihood or LR*).ti,ab. or exp Diagnostic Errors/ or (inter-observer or intra-observer or interobserver or intraobserver or validity or kappa or reliability).ti,ab. or reproducibility.ti,ab. or (test adj2 (re-test or retest)).ti,ab. or "Reproducibility of Results"/ or accuracy.ti,ab. or Diagnosis, Differential/ or Validation Study/ or ((false or true) adj3 (negative or positive)).ti,ab.	5552273
4	(1 and 2 and 3) not ((exp animals/ or exp models, animal/) not humans/) not ((letter/ or comment/ or editorial/) not (exp Clinical Trial/ or exp Meta-Analysis/ or exp Scoping Review/ or exp Systematic Review/))	451
5	limit 4 to yr="2005 -Current"	320
6	exp Meta-Analysis/ or exp Network Meta-Analysis/ or exp Systematic Review/ or (networkmeta analy* or networkmetaanaly* or metaanaly* or meta analy* or metanaly* or prisma or prospero or metaanali* or meta anali* or metanali*).ti,ab,kf. or ((systemati* or scoping or umbrella or structured literature) adj3 (review* or overview*)).ti,ab,kf. or ((structured or systemic*) adj3 (review* or overview* or synth*) adj3 literature).ti,ab,kf. or (systemic* adj1 review*).ti,ab,kf. or ((systemati* or literature or database* or data base*) adj10 search*).ti,ab,kf. or ((structured or comprehensive* or systemic*) adj3 search*).ti,ab,kf. or ((literature adj3 (review* or overview*)) and (search* or database* or data base*)).ti,ab,kf. or ((data extraction* or data source*) and (study selection* or studies selection*)).ti,ab,kf. or (search strateg* and selection criteria*).ti,ab,kf. or (data source* and data synth*).ti,ab,kf. or (medline* or pubmed* or pub med* or embase or cochrane*).ti,ab,kf. or cochrane.jw. or ((critical* or rapid*) adj2 (review* or overview* or synth*)).ti. or (((critical* or rapid*) adj3 (review* or overview* or synth*)) and (search* or database* or data base*)).ab. or metasynth*.ti,ab,kf. or meta synth*.ti,ab,kf.	863982
7	exp clinical trial/ or randomized controlled trial/ or exp clinical trials as topic/ or randomized controlled trials as topic/ or Random Allocation/ or Double-Blind Method/ or Single-Blind Method/ or (clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or controlled clinical trial or randomized controlled trial or multicenter study or clinical trial).pt. or random*.ti,ab. or (clinic* adj trial*).tw. or ((singl* or doubl* or treb* or tripl*) adj (blind$3 or mask$3)).tw. or Placebos/ or placebo*.tw.	2950575
8	Case-control Studies/ or clinical trial, phase ii/ or clinical trial, phase iii/ or clinical trial, phase iv/ or comparative study/ or control groups/ or controlled before-after studies/ or controlled clinical trial/ or double-blind method/ or historically controlled study/ or matched-pair analysis/ or single-blind method/ or (((control or controlled) adj6 (study or studies or trial)) or (compar* adj (study or studies)) or ((control or controlled) adj1 active) or "open label*" or ((double or two or three or multi or trial) adj (arm or arms)) or (allocat* adj10 (arm or arms)) or placebo* or "sham-control*" or ((single or double or triple or assessor) adj1 (blind* or masked)) or nonrandom* or "non-random*" or "quasi-experiment*" or "parallel group*" or "factorial trial" or "pretest posttest" or (phase adj5 (study or trial)) or (case* adj6 (matched or control*)) or (match* adj6 (pair or pairs or cohort* or control* or group* or healthy or age or sex or gender or patient* or subject* or participant*)) or (propensity adj6 (scor* or match*))).ti,ab,kf. or (confounding adj6 adjust*).ti,ab. or (versus or vs or compar*).ti. or exp cohort studies/ or epidemiologic studies/ or ((multicenter study/ or observational study/ or seroepidemiologic studies/ or (cohort* or 'follow up' or followup or longitudinal* or prospective* or retrospective* or observational* or multicent* or 'multi-cent*' or consecutive*).ti,ab,kf.) and ((group or groups or subgroup* or versus or vs or compar*).ti,ab,kf. or ('odds ratio*' or 'relative odds' or 'risk ratio*' or 'relative risk*' or aor or arr or rrr).ab. or (("OR" or "RR") adj6 CI).ab.)) or Case control.tw. or cohort.tw. or Cohort analy$.tw. or (Follow up adj (study or studies)).tw. or (observational adj (study or studies)).tw. or Longitudinal.tw. or Retrospective*.tw. or prospective*.tw. or consecutive*.tw. or Cross sectional.tw. or Cross-sectional studies/ or historically controlled study/ or interrupted time series analysis/	8188991
9	5 and 6	48
10	(5 and 7) not 9	31
11	(5 and 8) not (9 or 10)	96

12	9 or 10 or 11	175

Bijlagen bij module 3 – Ziekte van Creutzfeldt-Jakob

Implementatietabel

De implementatietabel brengt in kaart welke factoren de uitvoering van een aanbeveling
5 bevorderen of belemmeren, en welke aanvullende acties nodig zijn voor succesvolle invoering. De adviseur en (cluster)werkgroep vullen de tabel in op basis van gerichte vragen over het onderliggende probleem, relevante randvoorwaarden en mogelijke knelpunten. Op basis hiervan wordt geconcludeerd of een extra implementatie-impuls wenselijk is.

Vraag	***Antwoord:*** *Kruis aan en licht toe/ beschrijf*		***Toelichting keuze:***
I1. Wat was het onderliggende probleem om deze uitgangsvraag uit te werken?		**Ongewenste praktijkvariatie**	
	x	**Nieuwe evidentie**	Nieuwe test met duidelijke meerwaarde
		Anders	
I2. Maak een inschatting over hoeveel patiënten het ongeveer gaat waar de aanbeveling betrekking op heeft?	**x**	**< 1000**	
		< 5000	
		5000-40.000	
		> 40.000	
I3. Is de aanbeveling onderdeel van een bredere set interventies of verwant aan andere richtlijnen of modules? Zo ja, hoe verhoudt zij zich daartoe en moet hiermee rekening worden gehouden bij de implementatie, of kan de aanbeveling als losstaand worden beschouwd?		**Ja**	
	x	**Nee**	
I4. Belemmeringen en kansen op verschillende niveaus voor landelijke toepassing van de aanbeveling:		**Belemmerende factoren**	**Bevorderende factoren/ kansen**
Richtlijn/ klinisch traject (innovatie)	**x**		Al standaardzorg in meeste centra
Zorgverleners (artsen en verpleegkundigen)	**x**		Bekendheid met de richtlijn
Patiënt/ cliënt (naasten)			
Sociale context			
Organisatorische context	**x**		Centrale uitvoer al ingeregeld
Financiële en juridische context			
I5. A) Welke personen/partijen zijn van belang bij het toepassen van de aanbeveling in de praktijk? (kruis aan)		**A**	**B**
		Patiënt/ cliënt (naaste)	
B) Wat is er nodig van deze personen/partijen om de aanbeveling in de praktijk te kunnen brengen? *Denk aan aanpassingen in gedrag, werkwijzen,*	**x**	Professional	Kennisnemen van de richtlijn
	x	Beroepsvereniging, nl	Bekendheid met de richtlijn

beleid, samenwerking of andere randvoorwaarden.		Ziekenhuis (raad van bestuur/UMCNL (voorheen NFU)/NVZ)	
		Zorgverzekeraars/ NZa	
		Zorginstituut [duiding nodig]	
		Anders	
I6. Binnen welk tijdsbestek moet de aanbeveling zijn geïmplementeerd?	**x**	< 1 jaar	
		binnen 2-3 jaar	
I7. Conclusie: is er extra actie en/of ondersteuning nodig voor implementatie van de aanbeveling? *De reguliere implementatieroutes (publicatie en disseminatie via officiële kanalen, opname in professionele standaarden, scholing en nascholing, gebruik van bestaande ICT systemen, audits en visitaties) van de richtlijnmodule alleen is onvoldoende.*		Ja	
	x	Nee	
I8. Plaatsing op de Landelijke Implementatieagenda Medisch Specialistische zorg is gewenst. *Het gaat om zorg die (grotendeels) wordt uitgevoerd binnen de ziekenhuismuren. Succesvolle implementatie vraagt om actieve betrokkenheid en samenwerking van meerdere relevante partijen binnen de zorgpraktijk.*		Ja *	
	x	Nee	

**Deze aanbeveling komt mogelijk in aanmerking voor plaatsing op de Landelijke Implementatieagenda van het programma Zorg Evaluatie & Gepast Gebruik (ZE&GG), waarin alle betrokken partijen in de medisch-specialistische zorg samenwerken aan de implementatie van bewezen beste zorg. De Federatie levert namens het veld goed onderbouwde aanbevelingen aan, die zijn getoetst op de behoefte aan een implementatie-impuls. De onderwerpen op de Implementatieagenda zijn onderdeel van landelijke zorginkoopafspraken tussen zorgverzekeraars en zorgaanbieders. Voor de beoordeling van aanbevelingen uit richtlijnen wordt gebruikgemaakt van de implementatietabel. Op basis hiervan kunnen we de andere partijen goed informeren en gezamenlijk besluiten of plaatsing op de Implementatieagenda passend is.*

Risk of bias assessment diagnostic accuracy studies (QUADAS II, 2011)

Research question: *What is the diagnostic value of the RT-QuIC prion test in comparison to other diagnostic methods (MRI, EEG, 14-3-3 protein, and CSF tau) for identifying Creutzfeldt-Jakob disease in patients with rapidly progressive dementia?*

Study reference	Patient selection	Index test	Reference standard	Flow and timing	Comments with respect to applicability
Mastrangelo, 2022	Was a consecutive or random sample of patients enrolled? Yes Was a case-control design avoided? No Did the study avoid inappropriate exclusions? No	Were the index test results interpreted without knowledge of the results of the reference standard? Unclear If a threshold was used, was it pre-specified? Yes	Is the reference standard likely to correctly classify the target condition? Yes Were the reference standard results interpreted without knowledge of the results of the index test? Unclear	Was there an appropriate interval between index test(s) and reference standard? Unclear Did all patients receive a reference standard? No Did patients receive the same reference standard? No Were all patients included in the analysis? No	Are there concerns that the included patients do not match the review question? No Are there concerns that the index test, its conduct, or interpretation differ from the review question? No Are there concerns that the target condition as defined by the reference standard does not match the review question? No **RISK: LOW**
	CONCLUSION: Could the selection of patients have introduced bias? **RISK: UNCLEAR**	CONCLUSION: Could the conduct or interpretation of the index test have introduced bias? **RISK: UNCLEAR**	CONCLUSION: Could the reference standard, its conduct, or its interpretation have introduced bias? **RISK: UNCLEAR**	CONCLUSION Could the patient flow have introduced bias? **RISK: HIGH**	
Watson, 2022	Was a consecutive or random sample of patients enrolled? Yes Was a case-control design avoided? No Did the study avoid inappropriate exclusions? Unclear	Were the index test results interpreted without knowledge of the results of the reference standard? Unclear If a threshold was used, was it pre-specified? Yes	Is the reference standard likely to correctly classify the target condition? Yes Were the reference standard results interpreted without knowledge of the results of the index test? Unclear	Was there an appropriate interval between index test(s) and reference standard? Unclear Did all patients receive a reference standard? Yes	Are there concerns that the included patients do not match the review question? No Are there concerns that the index test, its conduct, or interpretation differ from the review question? No

Study reference	Patient selection	Index test	Reference standard	Flow and timing	Comments with respect to applicability
				Did patients receive the same reference standard? Yes Were all patients included in the analysis? No	Are there concerns that the target condition as defined by the reference standard does not match the review question? No **RISK: LOW**
	CONCLUSION: Could the selection of patients have introduced bias? **RISK: UNCLEAR**	CONCLUSION: Could the conduct or interpretation of the index test have introduced bias? **RISK: UNCLEAR**	CONCLUSION: Could the reference standard, its conduct, or its interpretation have introduced bias? **RISK: UNCLEAR**	CONCLUSION Could the patient flow have introduced bias? **RISK: HIGH**	

Table of excluded studies

Reference	Reason for exclusion
Rübsamen N, Pape S, Konigorski S, Zapf A, Rücker G, Karch A. Diagnostic accuracy of cerebrospinal fluid biomarkers for the differential diagnosis of sporadic Creutzfeldt-Jakob disease: a (network) meta-analysis. Eur J Neurol. 2022 May;29(5):1366-1376. doi: 10.1111/ene.15258. Epub 2022 Feb 8. PMID: 35075751.	Wrong population
Chatzikonstantinou S, Kazis D, Karantali E, Knights M, McKenna J, Petridis F, Mavroudis I. A meta-analysis on RT-QuIC for the diagnosis of sporadic CJD. Acta Neurol Belg. 2021 Apr;121(2):341-349. doi: 10.1007/s13760-021-01596-3. Epub 2021 Jan 24. PMID: 33486717.	Wrong population
Behaeghe O, Mangelschots E, De Vil B, Cras P. A systematic review comparing the diagnostic value of 14-3-3 protein in the cerebrospinal fluid, RT-QuIC and RT-QuIC on nasal brushing in sporadic Creutzfeldt-Jakob disease. Acta Neurol Belg. 2018 Sep;118(3):395-403. doi: 10.1007/s13760-018-0995-8. Epub 2018 Aug 10. PMID: 30097826.	Wrong population
Chang BK, Day GS, Graff-Radford J, McKeon A, Flanagan EP, Algeciras-Schimnich A, Mielke MM, Nguyen A, Jones DT, Toledano M, Kremers WK, Knopman DS, Petersen RC, Li W. Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt-Jakob disease and autoimmune encephalitis. Eur J Neurol. 2022 Oct;29(10):2905-2912. doi: 10.1111/ene.15469. Epub 2022 Jul 5. PMID: 35735602; PMCID: PMC9463096.	Wrong intervention Wrong population
Shir D, Lazar EB, Graff-Radford J, Aksamit AJ, Cutsforth-Gregory JK, Jones DT, Botha H, Ramanan VK, Prusinski C, Porter A, Day GS. Analysis of Clinical Features, Diagnostic Tests, and Biomarkers in Patients With Suspected Creutzfeldt-Jakob Disease, 2014-2021. JAMA Netw Open. 2022 Aug 1;5(8):e2225098. doi: 10.1001/jamanetworkopen.2022.25098. PMID: 35921110; PMCID: PMC9350714.	Wrong study design
Boll MC, Muñoz-López I, Cárdenas G, Ramírez-García MÁ, Nava-Galán MG, Yescas-Gómez P. Apparent Diffusion Coefficient Measurements. A Reliable Tool for the Diagnosis of Creutzfeldt-Jakob Disease. Arch Med Res. 2025 Feb;56(2):103104. doi: 10.1016/j.arcmed.2024.103104. Epub 2024 Oct 21. PMID: 39437617.	Wrong intervention Wrong population
Ng D, Watson N, McDermott EA, Kurucu H, Summers D, Andrews M, Green A, Barria M, McKenzie J, Tam J, Smith C, Pal S. Characterisation of RT-QuIC negative cases from the UK National CJD Research and Surveillance programme. J Neurol. 2024 Jul;271(7):4216-4226. doi: 10.1007/s00415-024-12345-w. Epub 2024 Apr 10. PMID: 38597944; PMCID: PMC11233280.	Wrong outcome
Fayolle M, Lehmann S, Delaby C. Comparison of cerebrospinal fluid tau, ptau(181), synuclein, and 14-3-3 for the detection of Creutzfeldt-Jakob disease in clinical practice. J Neural Transm (Vienna). 2022 Feb;129(2):133-139. doi: 10.1007/s00702-021-02443-8. Epub 2022 Jan 18. PMID: 35041062.	Wrong intervention
Foutz A, Appleby BS, Hamlin C, Liu X, Yang S, Cohen Y, Chen W, Blevins J, Fausett C, Wang H, Gambetti P, Zhang S, Hughson A, Tatsuoka C, Schonberger LB, Cohen ML, Caughey B, Safar JG. Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol. 2017 Jan;81(1):79-92. doi: 10.1002/ana.24833. PMID: 27893164; PMCID: PMC5266667.	Wrong study design
Senesi M, Lewis V, Varghese S, Stehmann C, McGlade A, Doecke JD, Ellett L, Sarros S, Fowler CJ, Masters CL, Li QX, Collins SJ. Diagnostic performance of CSF biomarkers in a well-characterized Australian cohort of sporadic Creutzfeldt-Jakob disease. Front Neurol. 2023 Feb 8;14:1072952. doi: 10.3389/fneur.2023.1072952. PMID: 36846121; PMCID: PMC9944944.	Wrong study design
Hermann P, Schmitz M, Cramm M, Goebel S, Bunck T, Schütte-Schmidt J, Schulz-Schaeffer W, Stadelmann C, Matschke J, Glatzel M, Zerr I. Application of real-time quaking-induced conversion in Creutzfeldt-Jakob disease surveillance. J Neurol. 2023 Apr;270(4):2149-2161. doi:	Wrong population Wrong comparator

10.1007/s00415-022-11549-2. Epub 2023 Jan 10. PMID: 36624183; PMCID: PMC9829526.	
Bizzi A, Pascuzzo R, Blevins J, Grisoli M, Lodi R, Moscatelli MEM, Castelli G, Cohen ML, Schonberger LB, Foutz A, Safar JG, Appleby BS, Gambetti P. Evaluation of a New Criterion for Detecting Prion Disease With Diffusion Magnetic Resonance Imaging. JAMA Neurol. 2020 Sep 1;77(9):1141-1149. doi: 10.1001/jamaneurol.2020.1319. PMID: 32478816; PMCID: PMC7265127.	Wrong indextest
Naranjo L, Sarto J, Nos C, Alcolea D, Rodríguez-Baz I, Navalpotro-Gómez I, Fernández-Lebrero A, Bertrán-Recasens B, Erro ME, Pelayo-Negro AL, Esteve C, Fernández S, Massot-Tarrús A, Boltes A, Torrents A, Guanyabens N, Palomino-García A, Egri N, Lladó A, Balasa M, Romera MA, Antón MDC, Couso RS, Sánchez-Valle R, Ruiz-García R; Spanish sCJD Study Group. Isolated CSF RT-QuIC positivity associates with a less aggressive disease course and decreased levels of neuronal/glial damage biomarkers in patients with sporadic Creutzfeldt-Jakob disease. J Neurol. 2025 Feb 11;272(3):198. doi: 10.1007/s00415-024-12757-8. PMID: 39932589.	Wrong study design
Rudge P, Hyare H, Green A, Collinge J, Mead S. Imaging and CSF analyses effectively distinguish CJD from its mimics. J Neurol Neurosurg Psychiatry. 2018 May;89(5):461-466. doi: 10.1136/jnnp-2017-316853. Epub 2017 Nov 15. PMID: 29142140; PMCID: PMC5909756.	Wrong indextest
McGuire LI, Peden AH, Orrú CD, Wilham JM, Appleford NE, Mallinson G, Andrews M, Head MW, Caughey B, Will RG, Knight RS, Green AJ. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 2012 Aug;72(2):278-85. doi: 10.1002/ana.23589. PMID: 22926858; PMCID: PMC3458796.	Wrong population
Nonaka T, Ae R, Kosami K, Tange H, Kaneko M, Nakagaki T, Hamaguchi T, Sanjo N, Nakamura Y, Kitamoto T, Kuroiwa Y, Kasuga K, Doyu M, Tanaka F, Abe K, Murayama S, Yabe I, Mochizuki H, Matsushita T, Murai H, Aoki M, Fujita K, Harada M, Takao M, Tsukamoto T, Iwasaki Y, Yamada M, Mizusawa H, Satoh K, Nishida N. A Retrospective Cohort Study of a Newly Proposed Criteria for Sporadic Creutzfeldt-Jakob Disease. Diagnostics (Basel). 2024 Oct 30;14(21):2424. doi: 10.3390/diagnostics14212424. PMID: 39518392; PMCID: PMC11545003.	Wrong population
Bsoul R, Lund EL, Burns K, Andrews M, McKenzie N, Green A, Areškevičiūtė A. Improved Real-Time Quaking Induced Conversion for Early Diagnostics of Creutzfeldt-Jakob Disease in Denmark. Int J Mol Sci. 2023 Mar 23;24(7):6098. doi: 10.3390/ijms24076098. PMID: 37047069; PMCID: PMC10094695.	Wrong comparator
Park JH, Choi YG, Lee YJ, Park SJ, Choi HS, Choi KC, Choi EK, Kim YS. Real-Time Quaking-Induced Conversion Analysis for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease in Korea. J Clin Neurol. 2016 Jan;12(1):101-6. doi: 10.3988/jcn.2016.12.1.101. Epub 2015 Nov 4. PMID: 26541494; PMCID: PMC4712274.	Wrong comparator Wrong population
Sano K, Satoh K, Atarashi R, Takashima H, Iwasaki Y, Yoshida M, Sanjo N, Murai H, Mizusawa H, Schmitz M, Zerr I, Kim YS, Nishida N. Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay. PLoS One. 2013;8(1):e54915. doi: 10.1371/journal.pone.0054915. Epub 2013 Jan 25. PMID: 23372790; PMCID: PMC3556051.	Wrong population
Groveman BR, Orrú CD, Hughson AG, Bongianni M, Fiorini M, Imperiale D, Ladogana A, Pocchiari M, Zanusso G, Caughey B. Extended and direct evaluation of RT-QuIC assays for Creutzfeldt-Jakob disease diagnosis. Ann Clin Transl Neurol. 2016 Dec 27;4(2):139-144. doi: 10.1002/acn3.378. PMID: 28168213; PMCID: PMC5288466.	Wrong comparator
Jones SM, Lazar EB, Porter AL, Prusinski CC, Brier MR, Bucelli RC, Day GS. Real-time quaking-induced conversion assays for prions: Applying a sensitive but imperfect test in clinical practice. Eur J Neurol. 2023 Jul;30(7):1854-1860. doi: 10.1111/ene.15795. Epub 2023 Apr 3. PMID: 36940265; PMCID: PMC10247483.	Wrong study design

Tam J, Centola J, Kurudzhu H, Watson N, MacKenzie J, Leitch M, Hughes T, Green A, Summers D, Barria M, Smith C, Pal S. Sporadic Creutzfeldt-Jakob Disease in the young (50 and below): 10-year review of United Kingdom surveillance. J Neurol. 2023 Feb;270(2):1036-1046. doi: 10.1007/s00415-022-11467-3. Epub 2022 Nov 5. PMID: 36334135; PMCID: PMC9886636.	Wrong population

Literature search strategy

Algemene informatie

Cluster/richtlijn: Cognitieve stoornissen en dementie	
Uitgangsvraag/modules: UV3 Wat is de aanbevolen diagnostische strategie om de ziekte van Creutzfeldt-Jakob vast te stellen in patiënten met snel progressieve dementie?	
Database(s): Embase.com, Ovid/Medline all	Datum: 26 augustus 2025
Periode: vanaf 2005	Talen: geen restrictie
Literatuurspecialist: Alies Oost	Rayyan: https://new.rayyan.ai/reviews/1594107/screening
BMI-zoekblokken: voor verschillende opdrachten wordt (deels) gebruik gemaakt van de zoekblokken van BMI-Online https://blocks.bmi-online.nl/	
Toelichting: De sleutelartikelen worden gevonden met de search. Maar 'Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease/ Hermann (2021)' komt niet door de filters voor studydesign (SR, RCT, observationeel), daarom zijn ook de overige artikelen meegenomen in het resultaat.	
Te gebruiken voor richtlijntekst: A systematic literature search was performed by a medical information specialist using the following bibliographic databases: Embase.com and Ovid/Medline all. Both databases were searched from 2005 to August 26th 2025 for systematic reviews, RCTs, observational and other studies. Systematic searches were completed using a combination of controlled vocabulary and natural language keywords. The overall search strategy was derived from the following primary search concepts: (1) dementia; (2) RT-QuIC prion test; (3) diagnostic accuracy. Duplicates were removed using EndNote software. After deduplication a total of 309 records were imported for title/abstract screening.	

Zoekopbrengst

	EMBASE	**OVID/MEDLINE**	**Ontdubbeld**
SR	12	10	13
RCT	21	23	40
Observationele studies	131	65	128
Overig	111	123	128
Totaal	275	221	**309***

****in Rayyan***

Zoekstrategie

Embase.com

No.	Query	Results
#1	'dementia'/exp OR 'parkinson disease'/exp OR dement*:ti,ab,kw OR alzheimer*:ti,ab,kw OR huntington*:ti,ab,kw OR ((lewy NEAR/1 bod*):ti,ab,kw) OR ((creutzfeld* NEAR/1 (jakob* OR jacob*)):ti,ab,kw) OR amenti*:ti,ab,kw OR (((pick OR picks OR 'pick s') NEAR/1 disease*):ti,ab,kw) OR parkinson*:ti,ab,kw	823135
#2	'real time quaking induced conversion'/exp OR 'real time quaking induced conversion assay'/exp OR 'rt quic':ti,ab,kw OR 'real time quaking induced conversion*':ti,ab,kw	1100
#3	'sensitivity and specificity'/de OR sensitivity:ab,ti OR specificity:ab,ti OR predict*:ab,ti OR 'roc curve':ab,ti OR 'receiver operator':ab,ti OR 'receiver operators':ab,ti OR likelihood:ab,ti OR 'diagnostic error'/exp OR 'diagnostic accuracy'/exp OR 'diagnostic test accuracy study'/exp OR 'inter observer':ab,ti OR 'intra observer':ab,ti OR interobserver:ab,ti OR intraobserver:ab,ti OR validity:ab,ti OR kappa:ab,ti OR reliability:ab,ti OR reproducibility:ab,ti OR ((test NEAR/2 're-	7090594

	test'):ab,ti) OR ((test NEAR/2 'retest'):ab,ti) OR 'reproducibility'/exp OR accuracy:ab,ti OR 'differential diagnosis'/exp OR 'validation study'/de OR 'measurement precision'/exp OR 'diagnostic value'/exp OR 'reliability'/exp OR 'predictive value'/exp OR ppv:ti,ab,kw OR npv:ti,ab,kw OR (((false OR true) NEAR/3 (negative OR positive)):ti,ab)	
#4	#1 AND #2 AND #3 NOT ('conference abstract'/it OR 'clinical trial':dtype) NOT (('editorial'/it OR 'letter'/it OR 'note'/it) NOT 'evidence based medicine'/exp) NOT (('animal'/exp OR 'animal experiment'/exp OR 'animal model'/exp OR 'nonhuman'/exp) NOT 'human'/exp) AND [2005-2025]/py	275
#5	'meta analysis'/exp OR 'systematic review'/exp OR 'scoping review'/exp OR 'rapid review'/exp OR 'umbrella review'/exp OR 'cochrane database of systematic reviews'/jt OR 'network meta-analysis'/exp OR 'networkmeta analy*':ti,ab,kw OR 'networkmetaanaly*':ti,ab,kw OR metaanaly*:ti,ab,kw OR 'meta analy*':ti,ab,kw OR metanaly*:ti,ab,kw OR prisma:ti,ab,kw OR prospero:ti,ab,kw OR metaanali*:ti,ab,kw OR 'meta anali*':ti,ab,kw OR metanali*:ti,ab,kw OR (((systemati* OR scoping OR umbrella OR 'structured literature') NEAR/3 (review* OR overview*)):ti,ab,kw) OR (((structured OR systemic*) NEAR/3 (review* OR overview* OR synth*) NEAR/3 literature):ti,ab,kw) OR ((systemic* NEAR/1 review*):ti,ab,kw) OR (((systemati* OR literature OR database* OR 'data base*') NEAR/10 search*):ti,ab,kw) OR (((structured OR comprehensive* OR systemic*) NEAR/3 search*):ti,ab,kw) OR (((literature NEAR/3 (review* OR overview*)):ti,ab,kw) AND (search*:ti,ab,kw OR database*:ti,ab,kw OR 'data base*':ti,ab,kw)) OR (('data extraction*':ti,ab,kw OR 'data source*':ti,ab,kw) AND ('study selection*':ti,ab,kw OR 'studies selection*':ti,ab,kw)) OR ('search strateg*':ti,ab,kw AND 'selection criteria*':ti,ab,kw) OR ('data source*':ti,ab,kw AND 'data synth*':ti,ab,kw) OR medline*:ti,ab,kw OR pubmed*:ti,ab,kw OR 'pub med*':ti,ab,kw OR embase:ti,ab,kw OR cochrane*:ti,ab,kw OR (((critical* OR rapid*) NEAR/2 (review* OR overview* OR synth*)):ti) OR ((((critical* OR rapid*) NEAR/3 (review* OR overview* OR synth*)):ab) AND (search*:ab OR database*:ab OR 'data base*':ab)) OR metasynth*:ti,ab,kw OR 'meta synth*':ti,ab,kw OR 'review* of review*':ti,ab,kw	1153573
#6	'clinical trial'/exp OR 'randomization'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp OR 'placebo'/exp OR 'prospective study'/exp OR rct:ab,ti OR random*:ab,ti OR 'single blind':ab,ti OR 'randomized controlled trial'/exp OR placebo*:ab,ti	4888660
#7	'major clinical study'/de OR 'clinical study'/de OR 'family study'/de OR 'longitudinal study'/de OR 'retrospective study'/de OR 'prospective study'/de OR 'cohort analysis'/de OR 'case control study'/de OR 'comparative study'/exp OR 'control group'/de OR 'controlled study'/de OR 'controlled clinical trial'/de OR 'crossover procedure'/de OR 'double blind procedure'/de OR 'phase 2 clinical trial'/de OR 'phase 3 clinical trial'/de OR 'phase 4 clinical trial'/de OR 'pretest posttest design'/de OR 'pretest posttest control group design'/de OR 'quasi experimental study'/de OR 'single blind procedure'/de OR 'triple blind procedure'/de OR ((cohort NEAR/1 (study OR studies)):ab,ti) OR (('case control' NEAR/1 (study OR studies)):ab,ti) OR (('follow up' NEAR/1 (study OR studies)):ab,ti) OR (observational NEAR/1 (study OR studies)) OR ((epidemiologic NEAR/1 (study OR studies)):ab,ti) OR (('cross sectional' NEAR/1 (study OR studies)):ab,ti) OR (((control OR controlled) NEAR/6 trial):ti,ab,kw) OR (((control OR controlled) NEAR/6 (study OR studies)):ti,ab,kw) OR (((control OR controlled) NEAR/1 active):ti,ab,kw) OR 'open label*':ti,ab,kw OR (((double OR two OR three OR multi OR trial) NEAR/1 (arm OR arms)):ti,ab,kw) OR ((allocat* NEAR/10 (arm OR arms)):ti,ab,kw) OR placebo*:ti,ab,kw OR 'sham-control*':ti,ab,kw OR (((single OR double OR triple OR assessor) NEAR/1 (blind* OR masked)):ti,ab,kw) OR nonrandom*:ti,ab,kw OR 'non-random*':ti,ab,kw OR 'quasi-experiment*':ti,ab,kw OR crossover:ti,ab,kw OR 'cross over':ti,ab,kw OR 'parallel group*':ti,ab,kw OR 'factorial trial':ti,ab,kw OR ((phase NEAR/5 (study OR trial)):ti,ab,kw) OR ((case* NEAR/6 (matched OR control*)):ti,ab,kw) OR ((match* NEAR/6 (pair OR pairs OR cohort* OR control* OR group* OR healthy OR age OR sex OR gender OR patient* OR subject* OR participant*)):ti,ab,kw) OR ((propensity NEAR/6 (scor* OR match*)):ti,ab,kw) OR versus:ti OR vs:ti OR compar*:ti OR ((compar* NEAR/1 study):ti,ab,kw) OR (('observational study'/de OR 'cross-sectional study'/de OR 'multicenter study'/de OR 'correlational study'/de OR 'follow up'/de OR cohort*:ti,ab,kw OR 'follow up':ti,ab,kw OR followup:ti,ab,kw OR longitudinal*:ti,ab,kw OR	18948181

	prospective*:ti,ab,kw OR retrospective*:ti,ab,kw OR observational*:ti,ab,kw OR 'cross sectional*':ti,ab,kw OR cross?ectional*:ti,ab,kw OR multicent*:ti,ab,kw OR 'multi-cent*':ti,ab,kw OR consecutive*:ti,ab,kw) AND (group:ti,ab,kw OR groups:ti,ab,kw OR subgroup*:ti,ab,kw OR versus:ti,ab,kw OR vs:ti,ab,kw OR compar*:ti,ab,kw OR 'odds ratio*':ab OR 'relative odds':ab OR 'risk ratio*':ab OR 'relative risk*':ab OR 'rate ratio':ab OR aor:ab OR arr:ab OR rrr:ab OR ((('or' OR 'rr') NEAR/6 ci):ab)))	
#8	#4 AND #5	12
#9	#4 AND #6 NOT #8	21
#10	#4 AND #7 NOT (#8 OR #9)	131
#11	#4 NOT (#8 OR #9 OR #10)	111

Ovid/Medline

#	Searches	Results
1	exp Dementia/ or exp Parkinsonian Disorders/ or dement*.ti,ab,kf. or alzheimer*.ti,ab,kf. or huntington*.ti,ab,kf. or (lewy adj1 bod*).ti,ab,kf. or (creutzfeld* adj1 (jakob* or jacob*)).ti,ab,kf. or amenti*.ti,ab,kf. or ((pick or picks or 'pick s') adj1 disease*).ti,ab,kf. or parkinson*.ti,ab,kf.	518380
2	('RT QuIC' or 'real time quaking induced conversion*').ti,ab,kf.	637
3	exp "Sensitivity and Specificity"/ or (sensitivity or specificity).ti,ab. or (predict* or ROC-curve or receiver-operator*).ti,ab. or (likelihood or LR*).ti,ab. or exp Diagnostic Errors/ or (inter-observer or intra-observer or interobserver or intraobserver or validity or kappa or reliability).ti,ab. or reproducibility.ti,ab. or (test adj2 (re-test or retest)).ti,ab. or "Reproducibility of Results"/ or accuracy.ti,ab. or Diagnosis, Differential/ or Validation Study/ or ((false or true) adj3 (negative or positive)).ti,ab.	5513617
4	(1 and 2 and 3) not ((exp animals/ or exp models, animal/) not humans/) not ((letter/ or comment/ or editorial/) not (exp Clinical Trial/ or exp Meta-Analysis/ or exp Scoping Review/ or exp Systematic Review/))	221
5	limit 4 to yr="2005 -Current"	221
6	exp Meta-Analysis/ or exp Network Meta-Analysis/ or exp Systematic Review/ or (networkmeta analy* or networkmetaanaly* or metaanaly* or meta analy* or metanaly* or prisma or prospero or metaanali* or meta anali* or metanali*).ti,ab,kf. or ((systemati* or scoping or umbrella or structured literature) adj3 (review* or overview*)).ti,ab,kf. or ((structured or systemic*) adj3 (review* or overview* or synth*) adj3 literature).ti,ab,kf. or (systemic* adj1 review*).ti,ab,kf. or ((systemati* or literature or database* or data base*) adj10 search*).ti,ab,kf. or ((structured or comprehensive* or systemic*) adj3 search*).ti,ab,kf. or ((literature adj3 (review* or overview*)) and (search* or database* or data base*)).ti,ab,kf. or ((data extraction* or data source*) and (study selection* or studies selection*)).ti,ab,kf. or (search strateg* and selection criteria*).ti,ab,kf. or (data source* and data synth*).ti,ab,kf. or (medline* or pubmed* or pub med* or embase or cochrane*).ti,ab,kf. or cochrane.jw. or ((critical* or rapid*) adj2 (review* or overview* or synth*)).ti. or (((critical* or rapid*) adj3 (review* or overview* or synth*)) and (search* or database* or data base*)).ab. or metasynth*.ti,ab,kf. or meta synth*.ti,ab,kf.	853595
7	exp clinical trial/ or randomized controlled trial/ or exp clinical trials as topic/ or randomized controlled trials as topic/ or Random Allocation/ or Double-Blind Method/ or Single-Blind Method/ or (clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or controlled clinical trial or randomized controlled trial or multicenter study or clinical trial).pt. or random*.ti,ab. or (clinic* adj trial*).tw. or ((singl* or doubl* or treb* or tripl*) adj (blind$3 or mask$3)).tw. or Placebos/ or placebo*.tw.	2932182
8	Case-control Studies/ or clinical trial, phase ii/ or clinical trial, phase iii/ or clinical trial, phase iv/ or comparative study/ or control groups/ or controlled before-after studies/ or controlled clinical trial/ or double-blind method/ or historically controlled study/ or matched-pair analysis/ or single-blind method/ or (((control or controlled) adj6 (study or studies or trial)) or (compar* adj (study or studies)) or ((control or controlled) adj1 active) or "open label*" or ((double or two or three or multi or trial) adj (arm or arms)) or (allocat* adj10 (arm or arms)) or placebo* or "sham-control*" or ((single or double or triple or assessor) adj1 (blind* or masked)) or nonrandom* or "non-random*" or "quasi-experiment*" or "parallel	8141722

	group*' or "factorial trial" or "pretest posttest" or (phase adj5 (study or trial)) or (case* adj6 (matched or control*)) or (match* adj6 (pair or pairs or cohort* or control* or group* or healthy or age or sex or gender or patient* or subject* or participant*)) or (propensity adj6 (scor* or match*))).ti,ab,kf. or (confounding adj6 adjust*).ti,ab. or (versus or vs or compar*).ti. or exp cohort studies/ or epidemiologic studies/ or ((multicenter study/ or observational study/ or seroepidemiologic studies/ or (cohort* or 'follow up' or followup or longitudinal* or prospective* or retrospective* or observational* or multicent* or 'multi-cent*' or consecutive*).ti,ab,kf.) and ((group or groups or subgroup* or versus or vs or compar*).ti,ab,kf. or ('odds ratio*' or 'relative odds' or 'risk ratio*' or 'relative risk*' or aor or arr or rrr).ab. or (("OR" or "RR") adj6 CI).ab.)) or Case control.tw. or cohort.tw. or Cohort analy$.tw. or (Follow up adj (study or studies)).tw. or (observational adj (study or studies)).tw. or Longitudinal.tw. or Retrospective*.tw. or prospective*.tw. or consecutive*.tw. or Cross sectional.tw. or Cross-sectional studies/ or historically controlled study/ or interrupted time series analysis/	
9	5 and 6	10
10	(5 and 7) not 9	23
11	(5 and 8) not (9 or 10)	65
12	5 not (9 or 10 or 11)	123

Bijlagen bij module 4 – Behandeling slaapstoornissen bij dementie

Implementatietabel

De implementatietabel brengt in kaart welke factoren de uitvoering van een aanbeveling
5 bevorderen of belemmeren, en welke aanvullende acties nodig zijn voor succesvolle invoering. De adviseur en (cluster)werkgroep vullen de tabel in op basis van gerichte vragen over het onderliggende probleem, relevante randvoorwaarden en mogelijke knelpunten. Op basis hiervan wordt geconcludeerd of een extra implementatie-impuls wenselijk is.

Vraag	***Antwoord:*** *Kruis aan en licht toe/ beschrijf*		***Toelichting keuze:***
I1. Wat was het onderliggende probleem om deze uitgangsvraag uit te werken?	**x**	**Ongewenste praktijkvariatie**	Er is aanzienlijke variatie in de klinische praktijk bij de behandeling van slaapstoornissen bij mensen met dementie, veroorzaakt door beperkt, inconsistent en vaak laagwaardig bewijs voor zowel farmacologische als niet-farmacologische interventies.
		Nieuwe evidentie	
		Anders	
I2. Maak een inschatting over hoeveel patiënten het ongeveer gaat waar de aanbeveling betrekking op heeft?		**< 1000**	
		< 5000	
		5000-40.000	
	x	**> 40.000**	
I3. Is de aanbeveling onderdeel van een bredere set interventies of verwant aan andere richtlijnen of modules? Zo ja, hoe verhoudt zij zich daartoe en moet hiermee rekening worden gehouden bij de implementatie, of kan de aanbeveling als losstaand worden beschouwd?	**x**	**Ja**	De aanbevelingen hangen samen met andere modules binnen dezelfde richtlijn, zoals de modules over antidepressiva en antipsychotica bij dementie.
		Nee	

I4. Belemmeringen en kansen op verschillende niveaus voor landelijke toepassing van de aanbeveling:		**Belemmerende factoren**	**Bevorderende factoren/ kansen**
Richtlijn/ klinisch traject (innovatie)		Lage kwaliteit van bewijs, kleine en inconsistente effecten.	Duidelijke stapsgewijze aanpak en focus op persoonsgerichte zorg.
Zorgverleners (artsen en verpleegkundigen)		Beperkte handvatten voor keuze van interventies.	Aandacht voor zorgvuldige anamnese en behandeling van onderliggende oorzaken.
Patiënt/ cliënt (naasten)		Hoge ziektelast en verwachtingen van effect.	Bereidheid om interventies te proberen, belang van samen-beslissen.
Sociale context		Intensieve inzet van mantelzorgers.	

Organisatorische context		Niet-farmacologische interventies zijn tijd- en organisatie-intensief, vooral buiten instellingen.	Betere uitvoerbaarheid binnen intramurale zorgsettings.
Financiële en juridische context		Geen kosteneffectiviteitsgegevens, mogelijke extra kosten voor middelen, personeel en monitoring.	Farmacologische interventies zijn doorgaans toegankelijk en onderdeel van standaardzorg.
I5. A) Welke personen/partijen zijn van belang bij het toepassen van de aanbeveling in de praktijk? (kruis aan) **B) Wat is er nodig van deze personen/partijen om de aanbeveling in de praktijk te kunnen brengen?** *Denk aan aanpassingen in gedrag, werkwijzen, beleid, samenwerking of andere randvoorwaarden.*		**A**	**B**
	x	Patiënt/ cliënt (naaste)	Betrokkenheid bij samen beslissen, realistische verwachtingen over effectiviteit.
	x	Professional	Zorgvuldige anamnese, focus op onderliggende oorzaken, terughoudend en kortdurend gebruik van medicatie, evalueren en staken bij uitblijven van effect.
		Beroepsvereniging, nl	
		Ziekenhuis (raad van bestuur/UMCNL (voorheen NFU)/NVZ)	
		Zorgverzekeraars/ NZa	
		Zorginstituut [duiding nodig]	
		Anders	
I6. Binnen welk tijdsbestek moet de aanbeveling zijn geïmplementeerd?	**x**	< 1 jaar	
		binnen 2-3 jaar	
I7. Conclusie: is er extra actie en/of ondersteuning nodig voor implementatie van de aanbeveling? *De reguliere implementatieroutes (publicatie en disseminatie via officiele kanalen, opname in professionele standaarden, scholing en nascholing, gebruik van bestaande ICT systemen, audits en visitaties) van de richtlijnmodule alleen is onvoldoende.*		Ja	
	x	Nee	De aanbevelingen sluiten grotendeels aan bij bestaande zorgprocessen. Reguliere implementatieroutes worden voldoende geacht.
I8. Plaatsing op de Landelijke Implementatieagenda Medisch Specialistische zorg is gewenst. *Het gaat om zorg die (grotendeels) wordt uitgevoerd binnen de ziekenhuismuren. Succesvolle implementatie vraagt om actieve betrokkenheid en samenwerking van meerdere relevante partijen binnen de zorgpraktijk.*		Ja *	
	x	Nee	De zorg betreft zowel intra- als extramurale settings en kent geen bewezen effectieve interventies waarvoor een specifieke

			implementatie-impuls binnen de medisch-specialistische zorg noodzakelijk is.

**Deze aanbeveling komt mogelijk in aanmerking voor plaatsing op de Landelijke Implementatieagenda van het programma Zorg Evaluatie & Gepast Gebruik (ZE&GG), waarin alle betrokken partijen in de medisch-specialistische zorg samenwerken aan de implementatie van bewezen beste zorg. De Federatie levert namens het veld goed onderbouwde aanbevelingen aan, die zijn getoetst op de behoefte aan een implementatie-impuls. De onderwerpen op de Implementatieagenda zijn onderdeel van landelijke zorginkoopafspraken tussen zorgverzekeraars en zorgaanbieders. Voor de beoordeling van aanbevelingen uit richtlijnen wordt gebruikgemaakt van de implementatietabel. Op basis hiervan kunnen we de andere partijen goed informeren en gezamenlijk besluiten of plaatsing op de Implementatieagenda passend is.*

Risk of Bias tables

Risk of bias assessment performed by McCleery (2020) is shown below:



Risk of bias assessment performed by Wilfling (2023) is shown below:



Table of excluded studies

Not applicable.

Literature search strategy

Algemene informatie

Cluster/richtlijn: Cognitieve stoornissen en dementie	
Uitgangsvraag/modules: UV4 Wat is de beste behandeling van slaapstoornissen bij patiënten met dementie?	
Database(s): Embase.com	Datum: 1 september 2025
Periode: vanaf 2005	Talen: geen restrictie
Literatuurspecialist: Alies Oost	Rayyan: https://new.rayyan.ai/reviews/1596874/screening
BMI-zoekblokken: voor verschillende opdrachten wordt (deels) gebruik gemaakt van de zoekblokken van BMI-Online https://blocks.bmi-online.nl/	
Toelichting: →De sleutelartikelen worden gevonden met de search. →Het betreft een oriënterende search in één database. →Vanwege de grote aantallen en de oriënterende aard van de search is specifiek gezocht door voor sleep disturbances or disorders met major trefwoord en woorden in titel te zoeken.	
Te gebruiken voor richtlijntekst: A systematic literature search was performed by a medical information specialist using the following bibliographic database: Embase.com. The database were searched from 2005 to September 1th 2025 for systematic reviews, RCTs and observational studies. A systematic search was completed using a combination of controlled vocabulary and natural language keywords. The overall search strategy was derived from the following primary search concepts: (1) dementia; (2) sleep disturbances or disorders. A total of 2361 records were imported for title/abstract screening.	

Zoekopbrengst

	EMBASE
SR	295
RCT	584
Observationele studies	1482
Totaal	2361

in Rayyan

Zoekstrategie

Embase.com

No.	Query	Results
#1	'dementia'/exp OR dement*:ti,ab,kw OR alzheimer*:ti,ab,kw OR huntington*:ti,ab,kw OR ((lewy NEAR/1 bod*):ti,ab,kw) OR ((creutzfeld* NEAR/1 (jakob* OR jacob*)):ti,ab,kw) OR amenti*:ti,ab,kw OR (((pick OR picks OR 'pick s') NEAR/1 disease*):ti,ab,kw)	619819
#2	'sleep disorder'/exp/mj OR 'sleep'/mj OR 'sleep quality'/mj OR 'sleep time'/mj OR 'sleep waking cycle'/mj OR ((sleep* NEAR/3 (disorder* OR atypical OR difficult* OR disturb* OR problem* OR interfer* OR perturbation* OR trouble OR fragmented OR inadequate OR improv* OR quality OR intervention* OR therap*)):ti) OR dyssomn*:ti OR insomn*:ti OR parasomn*:ti OR hypersomn*:ti OR narcolep*:ti OR somnolence:ti OR hypersomnolence:ti OR (((daytime OR 'day time') NEAR/3 (sleepiness OR drowsiness)):ti)	237371
#3	#1 AND #2 NOT ('conference abstract'/it OR 'clinical trial':dtype) NOT (('editorial'/it OR 'letter'/it OR 'note'/it) NOT 'evidence based medicine'/exp) NOT (('animal'/exp OR 'animal experiment'/exp OR 'animal model'/exp OR 'nonhuman'/exp) NOT 'human'/exp)	4319
#4	#3 AND [2005-2025]/py	3605
#5	'meta analysis'/exp OR 'systematic review'/exp OR 'scoping review'/exp OR 'rapid review'/exp OR 'umbrella review'/exp OR 'cochrane database of systematic reviews'/jt OR 'network meta-analysis'/exp OR 'networkmeta analy*':ti,ab,kw OR 'networkmetaanaly*':ti,ab,kw OR metaanaly*:ti,ab,kw OR 'meta analy*':ti,ab,kw OR metanaly*:ti,ab,kw OR prisma:ti,ab,kw OR prospero:ti,ab,kw OR metaanali*:ti,ab,kw OR 'meta anali*':ti,ab,kw OR metanali*:ti,ab,kw OR (((systemati* OR scoping OR umbrella OR 'structured literature') NEAR/3 (review* OR overview*)):ti,ab,kw) OR (((structured OR systemic*) NEAR/3 (review* OR overview* OR synth*) NEAR/3 literature):ti,ab,kw) OR ((systemic* NEAR/1 review*):ti,ab,kw) OR (((systemati* OR literature OR database* OR 'data base*') NEAR/10 search*):ti,ab,kw) OR (((structured OR comprehensive* OR systemic*) NEAR/3 search*):ti,ab,kw) OR (((literature NEAR/3 (review* OR overview*)):ti,ab,kw) AND (search*:ti,ab,kw OR database*:ti,ab,kw OR 'data	1155382

	base*':ti,ab,kw)) OR (('data extraction*':ti,ab,kw OR 'data source*':ti,ab,kw) AND ('study selection*':ti,ab,kw OR 'studies selection*':ti,ab,kw)) OR ('search strateg*':ti,ab,kw AND 'selection criteria*':ti,ab,kw) OR ('data source*':ti,ab,kw AND 'data synth*':ti,ab,kw) OR medline*:ti,ab,kw OR pubmed*:ti,ab,kw OR 'pub med*':ti,ab,kw OR embase:ti,ab,kw OR cochrane*:ti,ab,kw OR (((critical* OR rapid*) NEAR/2 (review* OR overview* OR synth*)):ti) OR ((((critical* OR rapid*) NEAR/3 (review* OR overview* OR synth*)):ab) AND (search*:ab OR database*:ab OR 'data base*':ab)) OR metasynth*:ti,ab,kw OR 'meta synth*':ti,ab,kw OR 'review* of review*':ti,ab,kw	
#6	'clinical trial'/exp OR 'randomization'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp OR 'placebo'/exp OR 'prospective study'/exp OR rct:ab,ti OR random*:ab,ti OR 'single blind':ab,ti OR 'randomized controlled trial'/exp OR placebo*:ab,ti	4892447
#7	'major clinical study'/de OR 'clinical study'/de OR 'family study'/de OR 'longitudinal study'/de OR 'retrospective study'/de OR 'prospective study'/de OR 'cohort analysis'/de OR 'case control study'/de OR 'comparative study'/exp OR 'control group'/de OR 'controlled study'/de OR 'controlled clinical trial'/de OR 'crossover procedure'/de OR 'double blind procedure'/de OR 'phase 2 clinical trial'/de OR 'phase 3 clinical trial'/de OR 'phase 4 clinical trial'/de OR 'pretest posttest design'/de OR 'pretest posttest control group design'/de OR 'quasi experimental study'/de OR 'single blind procedure'/de OR 'triple blind procedure'/de OR ((cohort NEAR/1 (study OR studies)):ab,ti) OR (('case control' NEAR/1 (study OR studies)):ab,ti) OR (('follow up' NEAR/1 (study OR studies)):ab,ti) OR (observational NEAR/1 (study OR studies)) OR ((epidemiologic NEAR/1 (study OR studies)):ab,ti) OR (('cross sectional' NEAR/1 (study OR studies)):ab,ti) OR (((control OR controlled) NEAR/6 trial):ti,ab,kw) OR (((control OR controlled) NEAR/6 (study OR studies)):ti,ab,kw) OR (((control OR controlled) NEAR/1 active):ti,ab,kw) OR 'open label*':ti,ab,kw OR (((double OR two OR three OR multi OR trial) NEAR/1 (arm OR arms)):ti,ab,kw) OR ((allocat* NEAR/10 (arm OR arms)):ti,ab,kw) OR placebo*:ti,ab,kw OR 'sham-control*':ti,ab,kw OR (((single OR double OR triple OR assessor) NEAR/1 (blind* OR masked)):ti,ab,kw) OR nonrandom*:ti,ab,kw OR 'non-random*':ti,ab,kw OR 'quasi-experiment*':ti,ab,kw OR crossover:ti,ab,kw OR 'cross over':ti,ab,kw OR 'parallel group*':ti,ab,kw OR 'factorial trial':ti,ab,kw OR ((phase NEAR/5 (study OR trial)):ti,ab,kw) OR ((case* NEAR/6 (matched OR control*)):ti,ab,kw) OR ((match* NEAR/6 (pair OR pairs OR cohort* OR control* OR group* OR healthy OR age OR sex OR gender OR patient* OR subject* OR participant*)):ti,ab,kw) OR ((propensity NEAR/6 (scor* OR match*)):ti,ab,kw) OR versus:ti OR vs:ti OR compar*:ti OR ((compar* NEAR/1 study):ti,ab,kw) OR (('observational study'/de OR 'cross-sectional study'/de OR 'multicenter study'/de OR 'correlational study'/de OR 'follow up'/de OR cohort*:ti,ab,kw OR 'follow up':ti,ab,kw OR followup:ti,ab,kw OR longitudinal*:ti,ab,kw OR prospective*:ti,ab,kw OR retrospective*:ti,ab,kw OR observational*:ti,ab,kw OR 'cross sectional*':ti,ab,kw OR cross?ectional*:ti,ab,kw OR multicent*:ti,ab,kw OR 'multi-cent*':ti,ab,kw OR consecutive*:ti,ab,kw) AND (group:ti,ab,kw OR groups:ti,ab,kw OR subgroup*:ti,ab,kw OR versus:ti,ab,kw OR vs:ti,ab,kw OR compar*:ti,ab,kw OR 'odds ratio*':ab OR 'relative odds':ab OR 'risk ratio*':ab OR 'relative risk*':ab OR 'rate ratio':ab OR aor:ab OR arr:ab OR rrr:ab OR ((('or' OR 'rr') NEAR/6 ci):ab)))	18963791
#8	#4 AND #5	295
#9	#4 AND #6 NOT #8	584
#10	#4 AND #7 NOT (#8 OR #9)	1482
#11	#8 OR #9 OR #10	2361
#12	36594432:ui OR 27851868:ui	2
#13	#11 AND #12	2